Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS	4	OCT 03	MATHDI removed from STN
NEWS	5	OCT 04	CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS	6	OCT 13	New CAS Information Use Policies Effective October 17, 2005
NEWS	7	OCT 17	STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAplus documents for use in third-party analysis and visualization tools
NEWS	8	OCT 27	Free KWIC format extended in full-text databases
NEWS	9	OCT 27	DIOGENES content streamlined
NEWS	10	OCT 27	EPFULL enhanced with additional content
NEWS	11	NOV 14	CA/CAplus - Expanded coverage of German academic research
NEWS	12	NOV 30	REGISTRY/ZREGISTRY on STN(R) enhanced with experimental spectral property data
NEWS	13	DEC 05	CASREACT(R) - Over 10 million reactions available
NEWS	14	DEC 14	2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS	15	DEC 14	2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS	16	DEC 14	CA/CAplus to be enhanced with updated IPC codes
NEWS	17	DEC 16	MARPATprev will be removed from STN on December 31, 2005
NEWS	18	DEC 21	IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS	19	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/USPAT2

NEWS EXPRESS	DECEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005. V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:07:26 ON 27 DEC 2005

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:07:34 ON 27 DEC 2005

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 DEC 2005 HIGHEST RN 870675-00-6
DICTIONARY FILE UPDATES: 26 DEC 2005 HIGHEST RN 870675-00-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10776828\Struc 3.str



chain nodes :
7 19 20
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
1-19 6-8 7-19 9-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-12 9-10 10-11 11-12 13-18 13-14 14-15
15-16 16-17 17-18
exact/norm bonds :
1-2 1-6 1-19 2-3 3-4 4-5 5-6 6-8 7-19 8-9 8-12 9-10 9-20 10-11 11-12
13-18 13-14 14-15 15-16 16-17 17-18

G1:O,S

G2:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS 23:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



G1 O,S

G2 C,N

Structure attributes must be viewed using STN Express query preparation.

```
=> l1
SAMPLE SEARCH INITIATED 10:07:57 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       25 TO ITERATE

100.0% PROCESSED       25 ITERATIONS                                18 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          200 TO      800
PROJECTED ANSWERS:             106 TO      614

L2           18 SEA SSS SAM L1

=> l1 full
FULL SEARCH INITIATED 10:08:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      543 TO ITERATE

100.0% PROCESSED      543 ITERATIONS                              297 ANSWERS
SEARCH TIME: 00.00.01

L3          297 SEA SSS FUL L1

=> file caplus medline
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   161.33     161.54

FILE 'CAPLUS' ENTERED AT 10:08:10 ON 27 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE 'MEDLINE' ENTERED AT 10:08:10 ON 27 DEC 2005

=> l3
L4 3 L3

=> dup rem l3
DUPLICATE IS NOT AVAILABLE IN 'REGISTRY'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	6.77	168.31

FILE 'REGISTRY' ENTERED AT 10:08:19 ON 27 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 DEC 2005 HIGHEST RN 870675-00-6
DICTIONARY FILE UPDATES: 26 DEC 2005 HIGHEST RN 870675-00-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html
PROCESSING COMPLETED FOR L3
L5 297 DUP REM L3 (0 DUPLICATES REMOVED)

=> dup rem l4

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.43	168.74

FILE 'CAPLUS' ENTERED AT 10:08:26 ON 27 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 27 Dec 2005 VOL 144 ISS 1
FILE LAST UPDATED: 26 Dec 2005 (20051226/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html
PROCESSING COMPLETED FOR L4
L6 3 DUP REM L4 (0 DUPLICATES REMOVED)

=> file caplus medline

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.45	169.19

FILE 'CAPLUS' ENTERED AT 10:08:36 ON 27 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 10:08:36 ON 27 DEC 2005

=> dup rem l4
PROCESSING COMPLETED FOR L4
L7 3 DUP REM L4 (0 DUPLICATES REMOVED)

=> d ibib abs hitstr 1-3

L7 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:701975 CAPLUS
DOCUMENT NUMBER: 141:225304
TITLE: Preparation of cyclohexyl-substituted lactams as cytokine receptor modulating agents
INVENTOR(S): Cherney, Robert J.; Carter, Percy; Duncia, John V.; Gardner, Daniel S.; Santella, Joseph B.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 385 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004071460	A2	20040826	WO 2004-US4418	20040211

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,

GQ, GW, ML, MR, NE, SN, TD, TG
US 2004186140 A1 20040923 US 2004-776828 20040211
EP 1606255 A2 20051221 EP 2004-710294 20040211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRIORITY APPLN. INFO.: US 2003-446850P P 20030212
WO 2004-US4418 W 20040211
OTHER SOURCE(S): MARPAT 141:225304
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Cyclohexyl-substituted lactams I [A = (un)substituted saturated or partially saturated cycloalkyl or heterocycloalkyl group with 3-8 atoms; E = S(:O)pCHR3, CHR3NR3, C(:O)NR3, N(R3)C(:O)NR3, SO2N(R3), N(R3)SO2N(R3); G = (CHR10)n; J = CH2CH2, CH:CH un(substituted) with (R13)s; R1, R2 = (un)substituted aryl or heteroaryl ring; R3 = H, alkyl; R10 = H, (un)substituted alkyl (two R10 groups may together comprise a carbonyl group); R11, R12 (independently) = H, (un)substituted alkyl, aralkyl, heteroaralkyl, ε-hydroxyalkyl, ε-mercaptoalkyl, ε-alkoxyalkyl, etc.; R13 = H, (un)substituted alkyl; X = O, S; Z = bond, (un)substituted aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminosulfonyl, aminosulfonylamino, carbonylamino, oxycarbonylamino, aminocarbonyloxy, alkenediyl, methylene, etc.; m = 0-1; n = 0-3; s = 0-1] such as II are prepared as modulators of cytokine activity for the treatment of diseases associated with cytokines and their receptors such as inflammation, osteo- and rheumatoid arthritis, autoimmune diseases, HIV infection, inflammatory bowel disease, asthma, multiple sclerosis, and atherosclerosis. E.g., 1,4-cyclohexanedione mono(ethylene ketal) is lithiated and acylated with Et cyanoformate, reductively aminated with (S)-α-methylbenzylamine, subjected to reduction with lithium aluminum hydride followed by hydrogenolysis with palladium hydroxide and protection with Cbz anhydride to yield nonracemic III. E.g., III undergoes substitution at the primary carbon with 4-bromophenyl disulfide and tributylphosphine followed by oxidation with mCPBA, Stille methylation of the p-bromophenyl moiety, hydrogenolysis of the Cbz protecting group, acylation with N-Cbz-L-methionine, and S-methylation and cyclization with Me iodide and cesium carbonate to yield IV. E.g., IV undergoes acid-catalyzed deketalization, titanium-mediated Meerwein-Pondorff-Verley reduction with isopropylamine (giving a mixture of both epimers at the amine center), N-methylation with formaldehyde and sodium triacetoxyborohydride, hydrogenolysis of the Cbz protecting group on the aminopyrrolidinone, and acylation with 3-trifluoromethylbenzoic acid and HATU to yield II. The compds. are modulators of chemokine receptor activity (no data). In addition, methods of halolactamization and dehalogenation and reagents appropriate for such transformations are claimed.

IT **746666-74-0P 746666-82-0P 746666-83-1P**
746666-85-3P 746666-95-5P 746667-02-7P
746667-41-4P 746667-43-6P 746667-45-8P
746667-62-9P 746667-65-2P 746668-45-1P
746668-66-6P 746668-69-9P 746668-74-6P
746668-83-7P 746669-71-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of cyclohexyl-substituted lactams as modulators for cytokine receptor activity in the treatment of conditions such as inflammation, rheumatoid arthritis, asthma, multiple sclerosis, and atherosclerosis)

RN 746666-74-0 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-

[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746666-82-0 CAPLUS
CN Benzamide, N-[(3R)-1-[(1R,2S,4S)-4-azido-2-[[[4-(methylthio)phenyl]sulfonyl]methyl]cyclohexyl]-3-methyl-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 746666-83-1 CAPLUS
CN Benzamide, N-[(3R)-1-[(1R,2S,4S)-4-amino-2-[[[4-(methylthio)phenyl]sulfonyl]methyl]cyclohexyl]-3-methyl-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 746666-85-3 CAPLUS
CN Benzamide, N-[(3R)-3-methyl-1-[(1R,2S,4S)-4-[(1-methylethyl)amino]-2-[[[4-(methylthio)phenyl]sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 746666-95-5 CAPLUS
CN Urea, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[[[4-(methylthio)phenyl]sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746667-02-7 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-[(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746667-41-4 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[[2-[3-(trifluoromethyl)phenyl]-1,3-dioxolan-2-yl]methyl]-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 746667-43-6 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[[2-[3-(trifluoromethyl)phenyl]-1,3-dioxolan-2-yl]methyl]-, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 746667-45-8 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[2-oxo-2-[3-(trifluoromethyl)phenyl]ethyl]-, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 746667-62-9 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-amino-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[4-(trifluoromethyl)-1H-benzimidazol-2-yl]-, rel-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746667-61-8
CMF C25 H27 F3 N4 O3 S

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746667-65-2 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-[(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[4-(trifluoromethyl)-1H-benzimidazol-2-yl]-, rel-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746667-64-1
CMF C28 H33 F3 N4 O3 S

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-45-1 CAPLUS
CN Carbamic acid, [(1R,3R,4S)-4-[(3S)-2-oxo-3-[[3-(trifluoromethyl)benzoyl]amino]-1-pyrrolidinyl]-3-[(phenylsulfonyl)methyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-66-6 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-2-[[(4-chlorophenyl)sulfonyl]methyl]-4-[methyl(1-methylethyl)amino]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-fluoro-5-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746668-65-5
CMF C29 H34 Cl F4 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-69-9 CAPLUS
CN Benzamide, 3-chloro-N-[(3S)-1-[(1S,2R,4R)-2-[[(4-chlorophenyl)sulfonyl]methyl]-4-[methyl(1-methylethyl)amino]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746668-68-8
CMF C28 H35 Cl2 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-74-6 CAPLUS
CN Carbamic acid, [2-[[[(3S)-1-[(1S,2R,4R)-2-[[(4-chlorophenyl)sulfonyl]methyl]-4-[methyl(1-methylethyl)amino]cyclohexyl]-2-

oxo-3-pyrrolidinyl]amino]carbonyl]-4-(trifluoromethoxy)phenyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-83-7 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-2-[[(4-chlorophenyl)sulfonyl]methyl]-4-[methyl(1-methylethyl)amino]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746668-82-6
CMF C29 H35 Cl F3 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-71-6 CAPLUS
CN 4-Pyrimidinecarboxamide, 5-bromo-2-(1,1-dimethylethyl)-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-70-5
CMF C30 H42 Br N5 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT **746666-70-6P 746666-72-8P 746666-76-2P**
746666-77-3P 746666-79-5P 746666-81-9P
746666-86-4P 746666-88-6P 746666-90-0P
746666-93-3P 746666-97-7P 746666-99-9P
746667-00-5P 746667-04-9P 746667-06-1P

746667-08-3P 746667-12-9P 746667-27-6P
746667-30-1P 746667-33-4P 746667-47-0P
746667-49-2P 746667-50-5P 746667-52-7P
746667-53-8P 746667-55-0P 746667-56-1P
746667-58-3P 746667-59-4P 746667-61-8P
746667-64-1P 746667-67-4P 746667-68-5P
746667-70-9P 746667-71-0P 746667-73-2P
746667-74-3P 746667-76-5P 746667-77-6P
746667-79-8P 746667-80-1P 746667-82-3P
746667-83-4P 746667-85-6P 746667-86-7P
746667-88-9P 746667-89-0P 746667-91-4P
746667-92-5P 746667-94-7P 746667-95-8P
746667-97-0P 746667-98-1P 746668-00-8P
746668-01-9P 746668-03-1P 746668-04-2P
746668-06-4P 746668-07-5P 746668-09-7P
746668-10-0P 746668-12-2P 746668-13-3P
746668-15-5P 746668-16-6P 746668-18-8P
746668-19-9P 746668-21-3P 746668-22-4P
746668-24-6P 746668-25-7P 746668-27-9P
746668-28-0P 746668-30-4P 746668-31-5P
746668-33-7P 746668-34-8P 746668-36-0P
746668-37-1P 746668-39-3P 746668-40-6P
746668-42-8P 746668-43-9P 746668-47-3P
746668-48-4P 746668-50-8P 746668-51-9P
746668-52-0P 746668-53-1P 746668-54-2P
746668-56-4P 746668-58-6P 746668-60-0P
746668-62-2P 746668-64-4P 746668-65-5P
746668-68-8P 746668-71-3P 746668-72-4P
746668-76-8P 746668-77-9P 746668-79-1P
746668-80-4P 746668-82-6P 746668-85-9P
746668-86-0P 746668-88-2P 746668-90-6P
746668-91-7P 746668-93-9P 746668-95-1P
746668-96-2P 746668-98-4P 746668-99-5P
746669-01-2P 746669-02-3P 746669-04-5P
746669-05-6P 746669-07-8P 746669-08-9P
746669-17-0P 746669-18-1P 746669-19-2P
746669-20-5P 746669-22-7P 746669-23-8P
746669-25-0P 746669-26-1P 746669-28-3P
746669-29-4P 746669-30-7P 746669-31-8P
746669-32-9P 746669-33-0P 746669-34-1P
746669-35-2P 746669-36-3P 746669-37-4P
746669-38-5P 746669-39-6P 746669-40-9P
746669-41-0P 746669-42-1P 746669-43-2P
746669-44-3P 746669-45-4P 746669-46-5P
746669-47-6P 746669-48-7P 746669-49-8P
746669-50-1P 746669-51-2P 746669-52-3P
746669-53-4P 746669-54-5P 746669-55-6P
746669-56-7P 746669-57-8P 746669-59-0P
746669-61-4P 746669-62-5P 746669-63-6P
746669-64-7P 746669-65-8P 746669-66-9P
746669-67-0P 746669-68-1P 746669-69-2P
746669-70-5P 746669-72-7P 746669-73-8P
746669-74-9P 746669-75-0P 746669-76-1P
746669-77-2P 746669-78-3P 746669-79-4P
746669-80-7P 746669-81-8P 746669-83-0P
746669-84-1P 746669-85-2P 746669-86-3P
746669-87-4P 746669-88-5P 746669-89-6P
746669-90-9P 746669-91-0P 746669-92-1P
746669-93-2P 746669-94-3P 746669-95-4P
746669-96-5P 746669-97-6P 746669-98-7P
746669-99-8P 746670-00-8P 746670-01-9P
746670-02-0P 746670-03-1P 746670-04-2P
746670-05-3P 746670-06-4P 746670-07-5P

746670-08-6P 746670-09-7P 746670-10-0P
746670-11-1P 746670-12-2P 746670-13-3P
746670-15-5P 746670-17-7P 746670-18-8P
746670-19-9P 746670-20-2P 746671-78-3P
748165-37-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclohexyl-substituted lactams as modulators for cytokine receptor activity in the treatment of conditions such as inflammation, rheumatoid arthritis, asthma, multiple sclerosis, and atherosclerosis)

RN 746666-70-6 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[[(4-methylphenyl)sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746666-72-8 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4S)-4-[methyl(1-methylethyl)amino]-2-[[(4-methylphenyl)sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746666-76-2 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4S)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746666-77-3 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-[ethyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746666-79-5 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4S)-4-[ethyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746666-81-9 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-[(cyclopropylmethyl)(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746666-86-4 CAPLUS
CN Benzamide, N-[(3R)-3-methyl-1-[(1R,2S,4S)-4-[methyl(1-methylethyl)amino]-2-[[[4-(methylthio)phenyl]sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 746666-88-6 CAPLUS
CN Benzamide, N-[(3R)-3-methyl-1-[(1R,2S,4S)-4-[(1-methylethyl)-2-propynylamino]-2-[[[4-(methylthio)phenyl]sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 746666-90-0 CAPLUS
CN Benzamide, N-[(3R)-1-[(1R,2S,4S)-4-[(cyclopropylmethyl)(1-methylethyl)amino]-2-[[[4-(methylthio)phenyl]sulfonyl]methyl]cyclohexyl]-3-methyl-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 746666-93-3 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[[[4-(methylthio)phenyl]sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746666-97-7 CAPLUS
CN Benzenesulfonamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[[[4-(methylthio)phenyl]sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746666-99-9 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[[[4-(methylthio)phenyl]sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746667-00-5 CAPLUS
CN Urea, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746667-04-9 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-[(1-methylethyl)-2-propenylamino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746667-06-1 CAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[(1S,2R)-4-[(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-N-[3-(trifluoromethyl)phenyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746667-08-3 CAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[(1S,2R)-4-[(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-N-[3-(trifluoromethyl)phenyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746667-12-9 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-[(1-methylethyl)propylamino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746667-27-6 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[[[4-(methylthio)phenyl]sulfonyl]methyl]cyclohexyl]-3-[[[3-(trifluoromethyl)phenyl]methyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746667-30-1 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R)-4-[(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[2-[3-(trifluoromethyl)phenyl]ethyl]-, (3R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746667-29-8
CMF C29 H37 F3 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746667-33-4 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R)-4-[(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[2-[3-(trifluoromethyl)phenyl]ethyl]-, (3S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746667-32-3
CMF C29 H37 F3 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746667-47-0 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[2-oxo-2-[3-(trifluoromethyl)phenyl]ethyl]-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 746667-49-2 CAPLUS
CN 2-Pyrrolidinone, 3-[2-hydroxy-2-[3-(trifluoromethyl)phenyl]ethyl]-1-[(1R,2S,4S)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 746667-50-5 CAPLUS
CN 2-Pyrrolidinone, 3-[2-hydroxy-2-[3-(trifluoromethyl)phenyl]ethyl]-1-[(1R,2S,4S)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-rel-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 746667-49-2
CMF C30 H39 F3 N2 O4 S

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746667-52-7 CAPLUS
CN 2-Pyrrolidinone, 3-[2-hydroxy-2-[3-(trifluoromethyl)phenyl]ethyl]-1-[(1R,2S,4S)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 746667-53-8 CAPLUS
CN 2-Pyrrolidinone, 3-[2-hydroxy-2-[3-(trifluoromethyl)phenyl]ethyl]-1-[(1R,2S,4S)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclo

hexyl]-, (3R)-rel-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 746667-52-7
CMF C30 H39 F3 N2 O4 S

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746667-55-0 CAPLUS
CN 2-Pyrrolidinone, 3-[2-(methoxyimino)-2-[3-(trifluoromethyl)phenyl]ethyl]-1-[(1R,2S,4S)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 746667-56-1 CAPLUS
CN 2-Pyrrolidinone, 3-[2-(methoxyimino)-2-[3-(trifluoromethyl)phenyl]ethyl]-1-[(1R,2S,4S)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3R)-rel-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746667-55-0
CMF C31 H40 F3 N3 O4 S

Relative stereochemistry.
Double bond geometry unknown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746667-58-3 CAPLUS
CN 2-Pyrrolidinone, 3-[2-(methoxyimino)-2-[3-(trifluoromethyl)phenyl]ethyl]-1-[(1R,2S,4S)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 746667-59-4 CAPLUS
CN 2-Pyrrolidinone, 3-[2-(methoxyimino)-2-[3-(trifluoromethyl)phenyl]ethyl]-1-[(1R,2S,4S)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-rel-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746667-58-3
CMF C31 H40 F3 N3 O4 S

Relative stereochemistry.
Double bond geometry unknown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746667-61-8 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-amino-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[4-(trifluoromethyl)-1H-benzimidazol-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 746667-64-1 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-[(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[4-(trifluoromethyl)-1H-benzimidazol-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 746667-67-4 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[4-(trifluoromethyl)-1H-benzimidazol-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 746667-68-5 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[4-(trifluoromethyl)-1H-benzimidazol-2-yl]-, rel-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746667-67-4
CMF C29 H35 F3 N4 O3 S

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746667-70-9 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-[ethyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[4-(trifluoromethyl)-1H-benzimidazol-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 746667-71-0 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-[ethyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[4-(trifluoromethyl)-1H-benzimidazol-2-yl]-, rel-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746667-70-9
CMF C30 H37 F3 N4 O3 S

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746667-73-2 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-(diethylamino)-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[4-(trifluoromethyl)-1H-benzimidazol-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 746667-74-3 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-(diethylamino)-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[4-(trifluoromethyl)-1H-benzimidazol-2-yl]-, rel-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746667-73-2
CMF C29 H35 F3 N4 O3 S

Relative stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 746667-76-5 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-(1-naphthalenylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746667-77-6 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-(1-naphthalenylamino)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746667-76-5
CMF C31 H39 N3 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746667-79-8 CAPLUS
CN 2-Pyrrolidinone, 3-(benzo[b]thien-3-ylamino)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746667-80-1 CAPLUS
CN 2-Pyrrolidinone, 3-(benzo[b]thien-3-ylamino)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746667-79-8
CMF C29 H37 N3 O3 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746667-82-3 CAPLUS
CN 2-Pyrrolidinone, 3-[(6-chloro-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746667-83-4 CAPLUS
CN 2-Pyrrolidinone, 3-[(6-chloro-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746667-82-3
CMF C29 H36 Cl N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746667-85-6 CAPLUS
CN 2-Pyrrolidinone, 3-[(6,8-dichloro-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746667-86-7 CAPLUS
CN 2-Pyrrolidinone, 3-[(6,8-dichloro-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746667-85-6
CMF C29 H35 Cl2 N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746667-88-9 CAPLUS
CN Benzamide, 3,5-dichloro-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746667-89-0 CAPLUS
CN Benzamide, 3,5-dichloro-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746667-88-9
CMF C28 H35 Cl2 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746667-91-4 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746667-92-5 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethoxy)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746667-91-4
CMF C29 H36 F3 N3 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746667-94-7 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[(1E)-2-[3-(trifluoromethyl)phenyl]ethenyl]-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 746667-95-8 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[(1E)-2-[3-(trifluoromethyl)phenyl]ethenyl]-, (3S)-rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746667-94-7
CMF C30 H37 F3 N2 O3 S

Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746667-97-0 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[2-[3-(trifluoromethyl)phenyl]-1-propenyl]-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 746667-98-1 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-[methyl(1-methylethyl)amino]-2-

[(phenylsulfonyl)methyl]cyclohexyl]-3-[2-[3-(trifluoromethyl)phenyl]-1-propenyl]-, (3S)-rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746667-97-0
CMF C31 H39 F3 N2 O3 S

Relative stereochemistry.
Double bond geometry unknown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-00-8 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-01-9 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746668-00-8
CMF C28 H37 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-03-1 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-04-2 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3,5-bis(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746668-03-1
CMF C30 H35 F6 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-06-4 CAPLUS
CN Benzamide, 2-amino-N-[(3R)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-07-5 CAPLUS
CN Benzamide, 2-amino-N-[(3R)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-4-(trifluoromethoxy)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746668-06-4
CMF C29 H37 F3 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-09-7 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[[6-(trifluoromethyl)-4-quinolinyl]amino]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-10-0 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[[6-(trifluoromethyl)-4-quinolinyl]amino]-, (3R)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746668-09-7
CMF C31 H37 F3 N4 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-12-2 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[[6-(trifluoromethyl)-4-quinolinyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-13-3 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[[6-(trifluoromethyl)-4-quinolinyl]amino]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746668-12-2
CMF C31 H37 F3 N4 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-15-5 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[[7-(trifluoromethyl)-4-quinolinyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-16-6 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[[7-(trifluoromethyl)-4-quinolinyl]amino]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746668-15-5
CMF C31 H37 F3 N4 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-18-8 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[[7-(trifluoromethyl)-4-quinolinyl]amino]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-19-9 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[[7-(trifluoromethyl)-4-quinolinyl]amino]-, (3R)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746668-18-8
CMF C31 H37 F3 N4 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-21-3 CAPLUS
CN 2-Pyrrolidinone, 3-([1,1'-biphenyl]-2-ylamino)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-22-4 CAPLUS
CN 2-Pyrrolidinone, 3-([1,1'-biphenyl]-2-ylamino)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746668-21-3
CMF C33 H41 N3 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-24-6 CAPLUS
CN 2-Pyrrolidinone, 3-[[3,5-bis(trifluoromethyl)phenyl]amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-25-7 CAPLUS
CN 2-Pyrrolidinone, 3-[[3,5-bis(trifluoromethyl)phenyl]amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746668-24-6
CMF C29 H35 F6 N3 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-27-9 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[[2-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-28-0 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[[2-(trifluoromethyl)phenyl]amino]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746668-27-9
CMF C28 H36 F3 N3 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-30-4 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[[2-(trifluoromethoxy)phenyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-31-5 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[[2-(trifluoromethoxy)phenyl]amino]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746668-30-4
CMF C28 H36 F3 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-33-7 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[[3-(trifluoromethyl)phenyl]amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-34-8 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[[3-(trifluoromethyl)phenyl]amino]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746668-33-7
CMF C28 H36 F3 N3 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-36-0 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-

[(phenylsulfonyl)methyl]cyclohexyl]-3-[[4-(trifluoromethyl)phenyl]amino]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-37-1 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-
[(phenylsulfonyl)methyl]cyclohexyl]-3-[[4-(trifluoromethyl)phenyl]amino]-,
trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746668-36-0
CMF C28 H36 F3 N3 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-39-3 CAPLUS
CN Benzamide, 3-chloro-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-40-6 CAPLUS
CN Benzamide, 3-chloro-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746668-39-3
CMF C28 H36 Cl N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-42-8 CAPLUS
CN Benzamide, 3-fluoro-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-43-9 CAPLUS
CN Benzamide, 3-fluoro-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-5-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746668-42-8
CMF C29 H35 F4 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-47-3 CAPLUS
CN Benzamide, N-[(3S)-2-oxo-1-[(1S,2R,4R)-4-(phenylamino)-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-pyrrolidinyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-48-4 CAPLUS
CN Benzamide, N-[(3S)-2-oxo-1-[(1S,2R,4R)-4-(phenylamino)-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-pyrrolidinyl]-3-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746668-47-3
CMF C31 H32 F3 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-50-8 CAPLUS
CN Benzamide, N-[2-oxo-1-[(1S,2R,4R)-2-[(phenylsulfonyl)methyl]-4-(3-pyridinylamino)cyclohexyl]-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-51-9 CAPLUS
CN Benzamide, N-[2-oxo-1-[(1S,2R,4R)-2-[(phenylsulfonyl)methyl]-4-(3-pyridinylamino)cyclohexyl]-3-pyrrolidinyl]-3-(trifluoromethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746668-50-8
CMF C30 H31 F3 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-52-0 CAPLUS
CN Benzamide, N-[2-oxo-1-[(1S,2R,4R)-2-[(phenylsulfonyl)methyl]-4-(2-thiazolylamino)cyclohexyl]-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-53-1 CAPLUS
CN Benzamide, N-[2-oxo-1-[(1S,2R,4R)-2-[(phenylsulfonyl)methyl]-4-(2-thiazolylamino)cyclohexyl]-3-pyrrolidinyl]-3-(trifluoromethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746668-52-0
CMF C28 H29 F3 N4 O4 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-54-2 CAPLUS
CN Carbamic acid, [(1R,3R,4S)-4-[(3S)-2-oxo-3-[[3-(trifluoromethyl)benzoyl]amino]-1-pyrrolidinyl]-3-[(phenylsulfonyl)methyl]cyclohexyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-56-4 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-(formylamino)-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-58-6 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-[(aminocarbonyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-60-0 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-[[(methylamino)carbonyl]amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-62-2 CAPLUS
CN Benzamide, N-[(3S)-2-oxo-1-[(1S,2R,4R)-4-(2-oxo-1-pyrrolidinyl)-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-64-4 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-(1,1-dioxido-2-isothiazolidinyl)-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-65-5 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-2-[[(4-chlorophenyl)sulfonyl]methyl]-4-[methyl(1-methylethyl)amino]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-fluoro-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-68-8 CAPLUS
CN Benzamide, 3-chloro-N-[(3S)-1-[(1S,2R,4R)-2-[[(4-chlorophenyl)sulfonyl]methyl]-4-[methyl(1-methylethyl)amino]cyclohexyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-71-3 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-2-[[(4-chlorophenyl)sulfonyl]methyl]-4-

[methyl(1-methylethyl)amino]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-72-4 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-2-[[(4-chlorophenyl)sulfonyl]methyl]-4-[methyl(1-methylethyl)amino]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3,5-bis(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746668-71-3
CMF C30 H34 Cl F6 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-76-8 CAPLUS
CN Benzamide, 2-amino-N-[(3S)-1-[(1S,2R,4R)-2-[[(4-chlorophenyl)sulfonyl]methyl]-4-[methyl(1-methylethyl)amino]cyclohexyl]-2-oxo-3-pyrrolidinyl]-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-77-9 CAPLUS
CN Benzamide, 2-amino-N-[(3S)-1-[(1S,2R,4R)-2-[[(4-chlorophenyl)sulfonyl]methyl]-4-[methyl(1-methylethyl)amino]cyclohexyl]-2-oxo-3-pyrrolidinyl]-5-(trifluoromethoxy)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746668-76-8
CMF C29 H36 Cl F3 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-79-1 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-2-[[(4-chlorophenyl)sulfonyl]methyl]-4-[methyl(1-methylethyl)amino]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-80-4 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-2-[[(4-chlorophenyl)sulfonyl]methyl]-4-[methyl(1-methylethyl)amino]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethoxy)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746668-79-1
CMF C29 H35 Cl F3 N3 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-82-6 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-2-[[(4-chlorophenyl)sulfonyl]methyl]-4-[methyl(1-methylethyl)amino]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-85-9 CAPLUS
CN Benzamide, 3,5-dichloro-N-[(3S)-1-[(1S,2R,4R)-2-[[(4-chlorophenyl)sulfonyl]methyl]-4-[methyl(1-methylethyl)amino]cyclohexyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-86-0 CAPLUS
CN Benzamide, 3,5-dichloro-N-[(3S)-1-[(1S,2R,4R)-2-[[(4-chlorophenyl)sulfonyl]methyl]-4-[methyl(1-methylethyl)amino]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746668-85-9
CMF C28 H34 Cl3 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-88-2 CAPLUS
CN Benzamide, 3-chloro-N-[(3S)-1-[(1S,2R,4R)-2-[[(4-chlorophenyl)sulfonyl]methyl]-4-[methyl(1-methylethyl)oxidoamino]cyclohexyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-90-6 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-2-[[(4-chlorophenyl)sulfonyl]methyl]-4-[methyl(1-methylethyl)oxidoamino]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-91-7 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-2-[[(4-chlorophenyl)sulfonyl]methyl]-4-[methyl(1-methylethyl)oxidoamino]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-fluoro-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-93-9 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)oxidoamino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-95-1 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-2-[[[4-(1-methylethyl)phenyl]sulfonyl]methyl]-4-[methyl(1-methylethyl)amino]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-96-2 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-2-[[[4-(1-methylethyl)phenyl]sulfonyl]methyl]-4-[methyl(1-methylethyl)amino]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746668-95-1
CMF C32 H42 F3 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746668-98-4 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[[(2-methylphenyl)sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746668-99-5 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[[(2-methylphenyl)sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746668-98-4
CMF C30 H38 F3 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-01-2 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-2-[[(4-fluorophenyl)sulfonyl]methyl]-4-[methyl(1-methylethyl)amino]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-02-3 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-2-[[(4-fluorophenyl)sulfonyl]methyl]-4-[methyl(1-methylethyl)amino]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746669-01-2
CMF C29 H35 F4 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-04-5 CAPLUS
CN Benzamide, 3-chloro-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[[(4-methylphenyl)sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-05-6 CAPLUS
CN Benzamide, 3-chloro-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[[(4-methylphenyl)sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746669-04-5
CMF C29 H38 Cl N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-07-8 CAPLUS
CN Benzamide, 2-amino-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[[(4-methylphenyl)sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-08-9 CAPLUS
CN Benzamide, 2-amino-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[[(4-methylphenyl)sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-5-(trifluoromethoxy)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-07-8
CMF C30 H39 F3 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-17-0 CAPLUS
CN 2-Pyrrolidinone, 3-[[6-chloro-2-(trifluoromethyl)-4-quinazolinyl]amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-18-1 CAPLUS
CN 2-Pyrrolidinone, 3-[[6-chloro-2-(trifluoromethyl)-4-quinazolinyl]amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-17-0
CMF C30 H35 Cl F3 N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-19-2 CAPLUS
CN 2-Pyrrolidinone, 3-[(7-chloro-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-20-5 CAPLUS
CN 2-Pyrrolidinone, 3-[(7-chloro-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-19-2
CMF C29 H36 Cl N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-22-7 CAPLUS
CN 2-Pyrrolidinone, 3-[(2,6-dichloro-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-23-8 CAPLUS
CN 2-Pyrrolidinone, 3-[(2,6-dichloro-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-22-7
CMF C29 H35 Cl2 N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-25-0 CAPLUS
CN 2-Pyrrolidinone, 3-[[6-chloro-2-(dimethylamino)-4-quinazolinyl]amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-26-1 CAPLUS
CN 2-Pyrrolidinone, 3-[[6-chloro-2-(dimethylamino)-4-quinazolinyl]amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-25-0
CMF C31 H41 Cl N6 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-28-3 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-[[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-29-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-[[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]amino]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-28-3
CMF C29 H36 Cl N5 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 746669-30-7 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[[6-(trifluoromethyl)-4-quinazolinyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-31-8 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[[6-(trifluoromethyl)-4-quinazolinyl]amino]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-30-7
CMF C30 H36 F3 N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 746669-32-9 CAPLUS
CN 2-Pyrrolidinone, 3-[[6-(1,1-dimethylethyl)thieno[3,2-d]pyrimidin-4-yl]amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-33-0 CAPLUS
CN 2-Pyrrolidinone, 3-[[6-(1,1-dimethylethyl)thieno[3,2-d]pyrimidin-4-yl]amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-32-9
CMF C31 H43 N5 O3 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-34-1 CAPLUS
CN 2-Pyrrolidinone, 3-[[6-(1,1-dimethylethyl)-2-(trifluoromethyl)thieno[3,2-d]pyrimidin-4-yl]amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-35-2 CAPLUS
CN 2-Pyrrolidinone, 3-[[6-(1,1-dimethylethyl)-2-(trifluoromethyl)thieno[3,2-d]pyrimidin-4-yl]amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-34-1
CMF C32 H42 F3 N5 O3 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-36-3 CAPLUS
CN 2-Pyrrolidinone, 3-[[6-(1,1-dimethylethyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-37-4 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[(6-tricyclo[3.3.1.13,7]dec-1-ylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-38-5 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-methyl-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-39-6 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-methyl-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-38-5
CMF C32 H41 N5 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-40-9 CAPLUS
CN 1H-Imidazole-5-carboxamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-2-phenyl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-41-0 CAPLUS
CN 1H-Imidazole-5-carboxamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-2-phenyl-1-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-40-9
CMF C38 H45 N5 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-42-1 CAPLUS
CN 1H-Imidazole-4-carboxamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-43-2 CAPLUS
CN 1H-Imidazole-4-carboxamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-42-1
CMF C31 H39 N5 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-44-3 CAPLUS
CN 2-Pyrrolidinone, 3-[(6,7-dimethoxy-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-45-4 CAPLUS
CN 2-Pyrrolidinone, 3-[(6,7-dimethoxy-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-44-3
CMF C31 H41 N5 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-46-5 CAPLUS
CN 2-Pyrrolidinone, 3-[(6-fluoro-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-47-6 CAPLUS
CN 2-Pyrrolidinone, 3-[(6-fluoro-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-46-5
CMF C29 H36 F N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-48-7 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[(6-methyl-4-quinazolinyl)amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-49-8 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[(6-methyl-4-quinazolinyl)amino]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-48-7
CMF C30 H39 N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-50-1 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[(6-phenylthieno[2,3-d]pyrimidin-4-yl)amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-51-2 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[(6-phenylthieno[2,3-d]pyrimidin-4-yl)amino]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-50-1
CMF C33 H39 N5 O3 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-52-3 CAPLUS
CN 2-Pyrrolidinone, 3-[(6-chloro-2-propyl-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-53-4 CAPLUS
CN 2-Pyrrolidinone, 3-[(6-chloro-2-propyl-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-52-3
CMF C32 H42 Cl N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-54-5 CAPLUS
CN 2-Pyrrolidinone, 3-[[6-chloro-2-(1-methylethyl)-4-quinazolinyl]amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-55-6 CAPLUS
CN 2-Pyrrolidinone, 3-[[6-chloro-2-(1-methylethyl)-4-quinazolinyl]amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-54-5
CMF C32 H42 Cl N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-56-7 CAPLUS
CN 2-Pyrrolidinone, 3-[[6-chloro-2-(1,1-dimethylethyl)-4-quinazolinyl]amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-57-8 CAPLUS
CN 2-Pyrrolidinone, 3-[[6-chloro-2-(1,1-dimethylethyl)-4-quinazolinyl]amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-56-7
CMF C33 H44 Cl N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-59-0 CAPLUS
CN 2-Pyrrolidinone, 3-[(6-chloro-2-methyl-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-58-9
CMF C30 H38 Cl N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-61-4 CAPLUS
CN 2-Pyrrolidinone, 3-[(6-chloro-2-ethyl-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-60-3
CMF C31 H40 Cl N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-62-5 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2,5-dioxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-63-6 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2,5-dioxo-3-pyrrolidinyl]-3-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746669-62-5
CMF C29 H34 F3 N3 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-64-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-4-tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-65-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-4-tricyclo[3.3.1.13,7]dec-1-yl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746669-64-7
CMF C36 H50 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-66-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 1-methyl-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-4-tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-67-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 1-methyl-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-4-tricyclo[3.3.1.13,7]dec-1-yl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746669-66-9
CMF C37 H52 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-68-1 CAPLUS
CN 2-Pyrrolidinone, 3-[[6-(1,1-dimethylethyl)pyrimido[5,4-d]pyrimidin-4-yl]amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-69-2 CAPLUS
CN 2-Pyrrolidinone, 3-[[6-(1,1-dimethylethyl)pyrimido[5,4-d]pyrimidin-4-yl]amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (2S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-68-1
CMF C31 H43 N7 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-70-5 CAPLUS
CN 4-Pyrimidinecarboxamide, 5-bromo-2-(1,1-dimethylethyl)-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-72-7 CAPLUS
CN 4-Pyrimidinecarboxamide, 2-(1,1-dimethylethyl)-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-5-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-73-8 CAPLUS
CN 4-Pyrimidinecarboxamide, 2-(1,1-dimethylethyl)-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-5-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-72-7
CMF C36 H47 N5 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-74-9 CAPLUS
CN Benzamide, 3-(1,1-dimethylethyl)-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-75-0 CAPLUS
CN Benzamide, 3-(1,1-dimethylethyl)-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746669-74-9
CMF C32 H45 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-76-1 CAPLUS
CN Benzamide, 3-bromo-5-(1,1-dimethylethyl)-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-77-2 CAPLUS
CN Benzamide, 3-bromo-5-(1,1-dimethylethyl)-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746669-76-1
CMF C32 H44 Br N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-78-3 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-(pyrido[2,3-d]pyrimidin-4-ylamino)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-79-4 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-

[(phenylsulfonyl)methyl]cyclohexyl]-3-(pyrido[2,3-d]pyrimidin-4-ylamino)-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-78-3
CMF C28 H36 N6 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-80-7 CAPLUS
CN 2-Pyrrolidinone, 3-[(6-chloropyrido[2,3-d]pyrimidin-4-yl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-81-8 CAPLUS
CN 2-Pyrrolidinone, 3-[(6-chloropyrido[2,3-d]pyrimidin-4-yl)amino]-1-

[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-80-7
CMF C28 H35 Cl N6 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-83-0 CAPLUS
CN 2-Pyrrolidinone, 3-[[6-chloro-2-(trifluoromethyl)pyrido[2,3-d]pyrimidin-4-yl]amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-82-9
CMF C29 H34 Cl F3 N6 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-84-1 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[[6-(trifluoromethoxy)-4-quinazolinyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-85-2 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[[6-(trifluoromethoxy)-4-quinazolinyl]amino]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-84-1
CMF C30 H36 F3 N5 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-86-3 CAPLUS
CN 2-Pyrrolidinone, 3-[[6-chloro-2-(methylamino)-4-quinazolinyl]amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-87-4 CAPLUS
CN 2-Pyrrolidinone, 3-[[6-chloro-2-(methylamino)-4-quinazolinyl]amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-86-3
CMF C30 H39 Cl N6 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-88-5 CAPLUS
CN 2-Pyrrolidinone, 3-[(6-fluoro-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[[(4-methylphenyl)sulfonyl]methyl]cyclohexyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-89-6 CAPLUS
CN 2-Pyrrolidinone, 3-[(6-fluoro-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[[(4-methylphenyl)sulfonyl]methyl]cyclohexyl]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-88-5
CMF C30 H38 F N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-90-9 CAPLUS
CN Benzamide, 2-chloro-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-91-0 CAPLUS
CN Benzamide, 2-chloro-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-5-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746669-90-9
CMF C29 H35 Cl F3 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-92-1 CAPLUS
CN 2-Pyrrolidinone, 3-[(6-bromo-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-93-2 CAPLUS
CN 2-Pyrrolidinone, 3-[(6-bromo-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-92-1
CMF C29 H36 Br N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-94-3 CAPLUS
CN 2-Pyrrolidinone, 3-[(6,7-difluoro-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-95-4 CAPLUS
CN 2-Pyrrolidinone, 3-[(6,7-difluoro-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-94-3
CMF C29 H35 F2 N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-96-5 CAPLUS
CN 2-Pyrrolidinone, 3-[(6-methoxy-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-97-6 CAPLUS
CN 2-Pyrrolidinone, 3-[(6-methoxy-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-96-5
CMF C30 H39 N5 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746669-98-7 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-(4-quinazolinylamino)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746669-99-8 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-(4-quinazolinylamino)-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746669-98-7
CMF C29 H37 N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746670-00-8 CAPLUS
CN [1,1'-Biphenyl]-3-carboxamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-01-9 CAPLUS
CN [1,1'-Biphenyl]-3-carboxamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746670-00-8
CMF C34 H41 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746670-02-0 CAPLUS
CN 2-Pyrrolidinone, 3-[(6-iodo-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-03-1 CAPLUS
CN 2-Pyrrolidinone, 3-[(6-iodo-4-quinazolinyl)amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746670-02-0
CMF C29 H36 I N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746670-04-2 CAPLUS
CN Benzamide, 3-(1,1-dimethylethyl)-4-hydroxy-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-05-3 CAPLUS
CN Benzamide, 3-(1,1-dimethylethyl)-4-hydroxy-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 746670-04-2
CMF C32 H45 N3 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746670-06-4 CAPLUS
CN 2-Thiophenecarboxamide, 3-amino-5-(1,1-dimethylethyl)-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-07-5 CAPLUS
CN 2-Thiophenecarboxamide, 3-amino-5-(1,1-dimethylethyl)-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclo

hexyl]-2-oxo-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746670-06-4
CMF C30 H44 N4 O4 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746670-08-6 CAPLUS
CN 3-Furancarboxamide, 2-methyl-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-5-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-09-7 CAPLUS
CN 3-Furancarboxamide, 2-methyl-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-5-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746670-08-6
CMF C33 H41 N3 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746670-10-0 CAPLUS
CN 2-Furancarboxamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-5-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-11-1 CAPLUS
CN 2-Furancarboxamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-5-nitro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746670-10-0
CMF C26 H34 N4 O7 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746670-12-2 CAPLUS
CN 2-Thiophenecarboxamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-13-3 CAPLUS
CN 2-Thiophenecarboxamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-4-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746670-12-2
CMF C32 H39 N3 O4 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746670-15-5 CAPLUS
CN Benzamide, N-[(3S)-2-oxo-1-[(1S,2R,4R)-2-[(phenylsulfonyl)methyl]-4-(1-pyrrolidinyl)cyclohexyl]-3-pyrrolidinyl]-3-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746670-14-4
CMF C29 H34 F3 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746670-17-7 CAPLUS
CN 1H-Imidazole-4-carboxamide, 1-methyl-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746670-16-6
CMF C32 H41 N5 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746670-18-8 CAPLUS
CN 1H-Imidazole-4-carboxamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-2-phenyl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-19-9 CAPLUS
CN 1H-Imidazole-4-carboxamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-2-phenyl-1-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746670-18-8
CMF C38 H45 N5 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746670-20-2 CAPLUS
CN 4-Pyrimidinecarboxamide, 2-(1,1-dimethylethyl)-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746671-78-3 CAPLUS
CN 4-Pyrimidinecarboxamide, 2-(1,1-dimethylethyl)-N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 746670-20-2
CMF C30 H43 N5 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 748165-37-9 CAPLUS
CN Benzamide, N-methyl-N-[(3S)-1-[4-[methyl(1-methylethyl)amino]-2-[[[4-(methylthio)phenyl]sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **746671-65-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of cyclohexyl-substituted lactams as modulators for cytokine receptor activity in the treatment of conditions such as inflammation, rheumatoid arthritis, asthma, multiple sclerosis, and atherosclerosis)
RN 746671-65-8 CAPLUS
CN Carbamic acid, [(3S)-1-[(1S,2R,4R)-4-azido-2-[[[4-(methylthio)phenyl]sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **746670-28-0P 746670-29-1P 746670-30-4P**
746670-31-5P 746670-34-8P 746670-35-9P
746670-36-0P 746670-37-1P 746670-41-7P
746670-42-8P 746670-43-9P 746670-44-0P
746670-45-1P 746670-56-4P 746670-57-5P
746670-58-6P 746670-70-2P 746670-71-3P
746670-72-4P 746670-73-5P 746670-74-6P
746670-75-7P 746670-76-8P 746670-77-9P
746670-78-0P 746670-79-1P 746670-80-4P
746670-81-5P 746670-82-6P 746670-83-7P
746670-84-8P 746670-96-2P 746670-97-3P
746670-98-4P 746670-99-5P 746671-00-1P
746671-01-2P 746671-02-3P 746671-03-4P
746671-04-5P 746671-12-5P 746671-13-6P
746671-14-7P 746671-15-8P 746671-22-7P
746671-24-9P 746671-25-0P 746671-26-1P
746671-48-7P 746671-49-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of cyclohexyl-substituted lactams as modulators for cytokine receptor activity in the treatment of conditions such as inflammation, rheumatoid arthritis, asthma, multiple sclerosis, and atherosclerosis)

RN 746670-28-0 CAPLUS

CN Carbamic acid, [(3S)-1-[(7R,8S)-7-[[(4-methylphenyl)sulfonyl]methyl]-1,4-dioxaspiro[4.5]dec-8-yl]-2-oxo-3-pyrrolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-29-1 CAPLUS

CN Carbamic acid, [(3S)-1-[(1S,2R)-2-[[(4-methylphenyl)sulfonyl]methyl]-4-oxocyclohexyl]-2-oxo-3-pyrrolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-30-4 CAPLUS
CN Carbamic acid, [(3S)-1-[(1S,2R,4R)-4-[(1-methylethyl)amino]-2-[[(4-methylphenyl)sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-31-5 CAPLUS
CN Carbamic acid, [(3S)-1-[(1S,2R,4S)-4-[(1-methylethyl)amino]-2-[[(4-methylphenyl)sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-34-8 CAPLUS
CN Carbamic acid, [(3R)-1-[(1R,2S,4S)-4-azido-2-[[[4-(methylthio)phenyl]sulfonyl]methyl]cyclohexyl]-3-methyl-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 746670-35-9 CAPLUS
CN Carbamic acid, [(3S)-1-[(1S,2R,4R)-4-amino-2-[[[4-(methylthio)phenyl]sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-36-0 CAPLUS
CN Carbamic acid, [(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[[[4-(methylthio)phenyl]sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-37-1 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-azido-2-[[[4-(methylthio)phenyl]sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-41-7 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 2-oxo-1-[(7R,8S)-7-[(phenylsulfonyl)methyl]-1,4-dioxaspiro[4.5]dec-8-yl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-42-8 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 2-oxo-1-[(7R,8S)-7-[(phenylsulfonyl)methyl]-1,4-dioxaspiro[4.5]dec-8-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-43-9 CAPLUS
CN 3-Pyrrolidinecarboxamide, 2-oxo-1-[(7R,8S)-7-[(phenylsulfonyl)methyl]-1,4-dioxaspiro[4.5]dec-8-yl]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-44-0 CAPLUS
CN 3-Pyrrolidinecarboxamide, 2-oxo-1-[(1S,2R)-4-oxo-2-[(phenylsulfonyl)methyl]cyclohexyl]-N-[3-(trifluoromethyl)phenyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-45-1 CAPLUS
CN 3-Pyrrolidinecarboxamide, 2-oxo-1-[(1S,2R)-4-oxo-2-[(phenylsulfonyl)methyl]cyclohexyl]-N-[3-(trifluoromethyl)phenyl]-, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-56-4 CAPLUS
CN 2-Pyrrolidinone, 1-[(7R,8S)-7-[(phenylsulfonyl)methyl]-1,4-dioxaspiro[4.5]dec-8-yl]-3-[2-[3-(trifluoromethyl)phenyl]ethyl]-, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-57-5 CAPLUS
CN 2-Pyrrolidinone, 1-[(7R,8S)-7-[(phenylsulfonyl)methyl]-1,4-dioxaspiro[4.5]dec-8-yl]-3-[2-[3-(trifluoromethyl)phenyl]ethyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-58-6 CAPLUS
CN 2-Pyrrolidinone, 1-[(1S,2R)-4-oxo-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[2-[3-(trifluoromethyl)phenyl]ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-70-2 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-azido-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[[2-[3-(trifluoromethyl)phenyl]-1,3-dioxolan-2-yl]methyl]-, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 746670-71-3 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-azido-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[[2-[3-(trifluoromethyl)phenyl]-1,3-dioxolan-2-yl]methyl]-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 746670-72-4 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-amino-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[[2-[3-(trifluoromethyl)phenyl]-1,3-dioxolan-2-yl]methyl]-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 746670-73-5 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-[(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[[2-[3-(trifluoromethyl)phenyl]-1,3-dioxolan-2-yl]methyl]-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 746670-74-6 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-[2-amino-3-(trifluoromethyl)phenyl]-1-[(1R,2S,4S)-4-azido-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 746670-75-7 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-azido-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[4-(trifluoromethyl)-1H-benzimidazol-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 746670-76-8 CAPLUS
CN Carbamic acid, [(3S)-1-[(1S,2R,4R)-4-azido-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-77-9 CAPLUS
CN Carbamic acid, [(3S)-1-[(1S,2R,4R)-4-amino-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-78-0 CAPLUS
CN Carbamic acid, [(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-79-1 CAPLUS
CN 2-Pyrrolidinone, 3-amino-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-80-4 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-azido-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[2-oxo-2-[3-(trifluoromethyl)phenyl]ethyl]-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 746670-81-5 CAPLUS
CN Methanesulfonic acid, trifluoro-, 2-[(3S)-1-[(1R,2S,4S)-4-azido-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-1-[3-(trifluoromethyl)phenyl]ethenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 746670-82-6 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-azido-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[(1E)-2-[3-(trifluoromethyl)phenyl]ethenyl]-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 746670-83-7 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-amino-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[(1E)-2-[3-(trifluoromethyl)phenyl]ethenyl]-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 746670-84-8 CAPLUS
CN 2-Pyrrolidinone, 1-[(1R,2S,4S)-4-azido-2-[(phenylsulfonyl)methyl]cyclohexyl]-3-[2-[3-(trifluoromethyl)phenyl]-1-propenyl]-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 746670-96-2 CAPLUS
CN Carbamic acid, [(3S)-1-[(1S,2R,4R)-4-[[(1,1-dimethylethoxy)carbonyl]amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-97-3 CAPLUS
CN Carbamic acid, [(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746670-98-4 CAPLUS
CN 2-Pyrrolidinone, 3-amino-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, dihydrobromide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HBr

RN 746670-99-5 CAPLUS
CN Carbamic acid, [2-[[[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]amino]carbonyl]-4-(trifluoromethoxy)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746671-00-1 CAPLUS
CN Carbamic acid, [(1R,3R,4S)-4-[(3S)-3-amino-2-oxo-1-pyrrolidinyl]-3-[(phenylsulfonyl)methyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746671-01-2 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-amino-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746671-02-3 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-amino-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 746671-01-2
CMF C25 H28 F3 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 746671-03-4 CAPLUS
CN Carbamic acid, [(1R,3R,4S)-4-[(3S)-2-oxo-3-[[3-(trifluoromethyl)benzoyl]amino]-1-pyrrolidinyl]-3-[(phenylsulfonyl)methyl]cyclohexyl]-, phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746671-04-5 CAPLUS
CN Benzamide, N-[(3S)-1-[(1S,2R,4R)-4-[(4-chloro-1-oxobutyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746671-12-5 CAPLUS
CN Carbamic acid, [(3S)-1-[(1S,2R,4R)-2-[[(4-chlorophenyl)sulfonyl]methyl]-4-[[(1,1-dimethylethoxy)carbonyl]amino]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746671-13-6 CAPLUS
CN Carbamic acid, [(3S)-1-[(1S,2R,4R)-4-amino-2-[[(4-chlorophenyl)sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746671-14-7 CAPLUS
CN Carbamic acid, [(3S)-1-[(1S,2R,4R)-2-[[(4-chlorophenyl)sulfonyl]methyl]-4-[methyl(1-methylethyl)amino]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746671-15-8 CAPLUS
CN 2-Pyrrolidinone, 3-amino-1-[(1S,2R,4R)-2-[[(4-chlorophenyl)sulfonyl]methyl]-4-[methyl(1-methylethyl)amino]cyclohexyl]-, dihydrobromide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HBr

RN 746671-22-7 CAPLUS
CN Carbamic acid, [(1R,3R,4S)-3-[[[4-(1-methylethyl)phenyl]sulfonyl]methyl]-4-[(3S)-2-oxo-3-[[3-(trifluoromethyl)benzoyl]amino]-1-pyrrolidinyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746671-24-9 CAPLUS
CN Carbamic acid, [1-[(1S,2R,4R)-4-[[(1,1-dimethylethoxy)carbonyl]amino]-2-[[(4-methylphenyl)sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746671-25-0 CAPLUS
CN 2-Pyrrolidinone, 3-amino-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[[(4-methylphenyl)sulfonyl]methyl]cyclohexyl]-, dihydrobromide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HBr

RN 746671-26-1 CAPLUS
CN Carbamic acid, [2-[[[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[[(4-methylphenyl)sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]amino]carbonyl]-4-(trifluoromethoxy)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746671-48-7 CAPLUS
CN Carbamic acid, [(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-2,5-dioxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746671-49-8 CAPLUS
CN 2,5-Pyrrolidinedione, 3-amino-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1987:439554 CAPLUS
DOCUMENT NUMBER: 107:39554
TITLE: Synthesis of dihydro-1H-pyrrolo- and tetrahydropyrido[1,2-a]indoles via a modified Madelung reaction
AUTHOR(S): Verboom, W.; Orlemans, E. O. M.; Berga, H. J.; Scheltinga, M. W.; Reinhoudt, D. N.
CORPORATE SOURCE: Lab. Org. Chem., Twente Univ. Technol., Enschede, 7500 AE, Neth.
SOURCE: Tetrahedron (1986), 42(18), 5053-64
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 107:39554
GI For diagram(s), see printed CA Issue.
AB Lactams I (R = cyano, tosyl, CO2CMe3; R1 = H, OMe; R2 = H, OMe, Me; n = 2, 3, 4, 5) cyclize under the influence of sodium hydride or potassium tert-butoxide. Depending on the ring size of the lactam moiety,

dihydropyrrolo[1,2-a]indoles II, tetrahydropyrido[1,2-a]indoles III, or dihydro-1H-1-benzazepine IV are formed. Starting from naphthaleneacetonitrile V, prepared in 5 steps from 2,3-dichloronaphthoquinone, the 5,10-dioxo-1H-pyrrolo[1,2-a]benz[f]indole VI is obtained upon treatment with base and subsequent oxidation of the protected hydroquinone function with ceric ammonium nitrate.

IT **109049-86-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and intramol. cyclocondensation of)

RN 109049-86-7 CAPLUS

CN 2-Pyrrolidinone, 1-[4,5-dimethoxy-2-[[(4-methylphenyl)sulfonyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1985:203345 CAPLUS

DOCUMENT NUMBER: 102:203345

TITLE: Cleaving of phthalimides

INVENTOR(S): Hagen, Helmut; Kohler, Rolf Dieter

PATENT ASSIGNEE(S): BASF A.-G. , Fed. Rep. Ger.

SOURCE: Ger. Offen., 7 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3319650	A1	19841206	DE 1983-3319650	19830531
EP 127114	A1	19841205	EP 1984-105830	19840522
EP 127114	B1	19861029		
R: CH, DE, FR, GB, LI				
JP 59231028	A2	19841225	JP 1984-109779	19840531

PRIORITY APPLN. INFO.: DE 1983-3319650 A 19830531

GI



I

AB Phthalimides I (R is an aromatic or heteroarom. residue) were cleaved by alkanolamines, preferably ethanolamine (II). Thus, 100 g I (R =

2-NCCH2C6H4) was added to 100 g II at 80° and, after 10 min, the mixture cooled to 20° and diluted with ice water to give 80% 2-NCCH2C6H4NH2.

IT **95539-55-2 95539-85-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(cleavage of, with alkanolamine)

RN 95539-55-2 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2,6-bis[(phenylsulfonyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 95539-85-8 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[(phenylsulfonyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	21.05	190.24
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.19	-2.19

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:16:25 ON 27 DEC 2005

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:

```
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS, MEDLINE' AT 10:19:11 ON 27 DEC 2005
FILE 'CAPLUS' ENTERED AT 10:19:11 ON 27 DEC 2005
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'MEDLINE' ENTERED AT 10:19:11 ON 27 DEC 2005

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      21.05     190.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -2.19      -2.19

=> log h
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      21.05     190.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -2.19      -2.19

 SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:19:29 ON 27 DEC 2005

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS, MEDLINE' AT 10:25:17 ON 27 DEC 2005
FILE 'CAPLUS' ENTERED AT 10:25:17 ON 27 DEC 2005
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'MEDLINE' ENTERED AT 10:25:17 ON 27 DEC 2005

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      21.05     190.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -2.19      -2.19

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      21.05     190.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -2.19      -2.19

FILE 'REGISTRY' ENTERED AT 10:25:25 ON 27 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)
```

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 DEC 2005 HIGHEST RN 870675-00-6
DICTIONARY FILE UPDATES: 26 DEC 2005 HIGHEST RN 870675-00-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10776828\Struc 4.str



chain nodes :
12 13 16
ring nodes :
1 2 3 4 5 6 7 8 9 10 11
chain bonds :
1-12 6-7 8-13 12-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 6-7 7-8 7-11 8-9 8-13 9-10 10-11
exact bonds :
1-12 12-16

G1:O,S

G2:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 16:CLASS

L8 STRUCTURE UPLOADED

=> d
L8 HAS NO ANSWERS
L8 STR



G1 O,S
G2 C,N

Structure attributes must be viewed using STN Express query preparation.

=> l8
SAMPLE SEARCH INITIATED 10:25:45 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 90 TO ITERATE

100.0% PROCESSED 90 ITERATIONS 10 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1231 TO 2369
PROJECTED ANSWERS: 11 TO 389

L9 10 SEA SSS SAM L8

=> l8 full
FULL SEARCH INITIATED 10:25:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1996 TO ITERATE

100.0% PROCESSED 1996 ITERATIONS 273 ANSWERS
SEARCH TIME: 00.00.01

L10 273 SEA SSS FUL L8

=> file caplus medline
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	161.33	351.57

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.19

FILE 'CAPLUS' ENTERED AT 10:26:01 ON 27 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'MEDLINE' ENTERED AT 10:26:01 ON 27 DEC 2005

=> l10
L11 161 L10

=> dup rem l11
PROCESSING COMPLETED FOR L11
L12 161 DUP REM L11 (0 DUPLICATES REMOVED)

=> d scan

L12 161 ANSWERS CAPLUS COPYRIGHT 2005 ACS on STN
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
TI Angular to linear rearrangement of an isoindolo[2,1-a]quinazoline skeleton
ST demethylation methoxyisoindoloquinazolinone rearrangement;
isoindoloquinazolinone methoxy demethylation rearrangement;
hydroxyisoindoloquinazolinone
IT Demethylation
Rearrangement
(angular to linear rearrangement of isoindoloquinazoline skeleton in demethylation reaction)
IT 628-13-7, Pyridine hydrochloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(angular to linear rearrangement of isoindoloquinazoline skeleton)
IT 19348-47-1P 159891-26-6P 159891-28-8P 159891-29-9P
159891-30-2P 159891-31-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(angular to linear rearrangement of isoindoloquinazoline skeleton)
IT 159891-27-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(angular to linear rearrangement of isoindoloquinazoline skeleton)
IT 85-44-9, Phthalic anhydride
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction with methoxymethylaniline)
IT 102-50-1, 4-Methoxy-2-methylaniline
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction with phthalic anhydride)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	6.29	357.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.19

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 10:26:47 ON 27 DEC 2005

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS, MEDLINE' AT 10:27:24 ON 27 DEC 2005
FILE 'CAPLUS' ENTERED AT 10:27:24 ON 27 DEC 2005
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'MEDLINE' ENTERED AT 10:27:24 ON 27 DEC 2005

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	6.29	357.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.19

=> d his

(FILE 'HOME' ENTERED AT 10:07:26 ON 27 DEC 2005)

FILE 'REGISTRY' ENTERED AT 10:07:34 ON 27 DEC 2005
L1 STRUCTURE UPLOADED
L2 18 L1
L3 297 L1 FULL

FILE 'CAPLUS, MEDLINE' ENTERED AT 10:08:10 ON 27 DEC 2005
L4 3 L3

FILE 'REGISTRY' ENTERED AT 10:08:19 ON 27 DEC 2005
L5 297 DUP REM L3 (0 DUPLICATES REMOVED)

FILE 'CAPLUS' ENTERED AT 10:08:26 ON 27 DEC 2005
L6 3 DUP REM L4 (0 DUPLICATES REMOVED)

FILE 'CAPLUS, MEDLINE' ENTERED AT 10:08:36 ON 27 DEC 2005
L7 3 DUP REM L4 (0 DUPLICATES REMOVED)

FILE 'REGISTRY' ENTERED AT 10:25:25 ON 27 DEC 2005
L8 STRUCTURE UPLOADED
L9 10 L8
L10 273 L8 FULL

FILE 'CAPLUS, MEDLINE' ENTERED AT 10:26:01 ON 27 DEC 2005
L11 161 L10
L12 161 DUP REM L11 (0 DUPLICATES REMOVED)

=> d l12 151-161 ibib abs hitstr

L12 ANSWER 151 OF 161 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1960:86368 CAPLUS
DOCUMENT NUMBER: 54:86368
ORIGINAL REFERENCE NO.: 54:16418b-h
TITLE: Synthesis of 1-phenyl-1,3-propanediol and derivatives

of 1-(substituted-phenyl)-1,3-propanediols via the Wohl-Ziegler reaction

AUTHOR(S): Owen, Tsung-Yao; Kao, Yee-Sheng
CORPORATE SOURCE: Acad. Sinica, Shanghai

SOURCE: Huaxue Xuebao (1959), 25, 312-20
CODEN: HHHPA4; ISSN: 0567-7351
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB A new route for the synthesis of 1-(substituted-phenyl)-1,3-propanediols via the Wohl-Ziegler reaction was described. 2,4-H2N(O2N)C6H3(CH2)3OH (I) (15 g.) in 150 ml. HCl-saturated AcOH was mixed with 8 g. AcCl in an ice bath and kept overnight to give 95% 2,4-H2N(O2N)C6H3(CH2)3OAc (II), m. 101-2° (MeOH), which yielded 81% 2,4-OHCNH(O2N)C6H3(CH2)3OAc, m. 113-14°, on warming with 90% HCO2H and 74% 2,4-EtO2CNH(O2N)C6H3(CH2)3OAc, m. 106-7°, on refluxing 1 hr. with ClCO2Et in EtOH and PhNMe2 solution Likewise, 2,4-HCl.H2NCH2(O2N)C6H3(CH2)3OH gave 85% 2,4-H2NCH2(O2N)C6H3(CH2)3OAc (III), isolated as the picrate, m. 203-4°. II (12 g.) and 8 g. phthalic anhydride (IV) mixed and heated 30 min. at 165-70° gave 82% 3-(2-phthalimido-4-nitrophenyl)propyl acetate (V), m. 123-4° (AcOEt), which (1 g.) was hydrolyzed (at the b.p. 2 hrs. with a mixture of 3 ml. AcOH, 3 ml. concentrated HCl, and 4 ml. H2O) to 75% II or (with a mixture of 10 ml. EtOH, 4 ml. concentrated HCl, and 8 ml. H2O) to 73% I, m. 89-90°. Similarly, III and IV gave 89% 3-(2-phthalimidomethyl-4-nitrophenyl)propyl acetate (VI), m. 165-6° (Et2O). Bromination of V, VI, Ph(CH2)3O2CC6H3(NO2)2-3,5, and 2,4-CN(O2N)C6H3(CH2)3OBz, resp., with bromosuccinimide at refluxing temperature 3 hrs. in dry CHCl3 in the presence of Bz2O2 gave the following 2,4-RR'C6H3CHBrCH2CH2OR'' (VII) (R, R', R'', % yield, and m.p. given): phthalimido, NO2, Ac (VIIa), 93, 136-7° (AcOEt); phthalimidomethyl, NO2, Ac, 88, 120°; H, H, 3,5-(NO2)2C6H3CO, 86, 121-2°; CN, NO2, Bz, 94, 105°. Refluxing 1 g. VIIa with 2 ml. 48% HBr in 10 ml. AcOH gave 0.2 g. 7-nitroquinoline, m. 132-3°. VII gave 2,4-RR'C6H3CH(OR''')CH2CH2OR'' (VIII) on refluxing at 110° 5 hrs. with AcOAg or AcOK in AcOH solution [R, R', R'', R''', % yield, m.p. (AcOEt) given]: phthalimido, NO2, Ac, H (VIIIa), 89, 139°; phthalimidomethyl, NO2, Ac, Ac, 82, 174°; H, H, 3,5-(NO2)2C6H3CO, Ac (VIIIb), 83, 152°; CN, NO2, Bz, Ac, 74, 120°. VIIIb (4 g.) was hydrolyzed by refluxing 4 hrs. with 15 ml. 10% aqueous KOH to 1.02 g. PhCH(OH)CH2CH2OH, b11 175°; di-p-nitrobenzoate m. 111°. VIIIa (1.5 g.) refluxed 2 hrs. with 4 ml. concentrated HCl in aqueous alc. and then mixed with 1.3 g. Cl2CHCOCl in 20 ml. 3% HCl and 6 g. AcONa at 0° gave 2,4-Cl2CHCONH(O2N)C6H3CH(OH)CH2CH2O2CCHCl2, m. 136° (AcOEt). o-O2NC6H4CH(OBz)CH2CH2OBz, m. 132°, was obtained by reduction of 2.5 g. o-O2NC6H4CH(OH)CH2CHO with 0.4 g. LiAlH4 in 30 ml. dry Et2O (reflux temperature, 2 hrs.) and then benzoylation of the product with BzCl in dry pyridine.

IT **101937-35-3**, Phthalimide, N-[2-(1-bromo-3-hydroxypropyl)-5-nitrophenyl]-, acetate
(preparation of)

RN 101937-35-3 CAPLUS

CN Phthalimide, N-[2-(1-bromo-3-hydroxypropyl)-5-nitrophenyl]-, acetate (6CI) (CA INDEX NAME)



L12 ANSWER 152 OF 161 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1959:17217 CAPLUS
DOCUMENT NUMBER: 53:17217
ORIGINAL REFERENCE NO.: 53:3195i,3196a-i,3197a-c
TITLE: New substituted o-phenylenediamines. II
AUTHOR(S): Cattapan, Domenico; Valcavi, Umberto; Alberti, Carlo G.
CORPORATE SOURCE: Farm. Italia, Milan
SOURCE: Gazzetta Chimica Italiana (1958), 88, 13-23
CODEN: GCITA9; ISSN: 0016-5603
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB cf. C.A. 52, 14549h. After many unsuccessful attempts 4,5,1,2-MePh(H2N)2C6H2 (I) was synthesized as a precursor of vitamin B12 analogs. Efforts to prepare the corresponding 4,5,1,2-Ph2(H2N)2C6H2 (II) led to 4,5,1,2-Ph(EtO2CNH)2C6H2 (III), saponified to 5,6-diphenylbenzimidazolone (IV), transformed by chlorination and hydrogenation to 5,6-diphenylbenzimidazole (V), also useful as an intermediate in the biosynthesis of vitamin B12. Ac2O (10 ml.) containing 3 drops of concentrated H2SO4 and 10 g. 2,4,5-Me(O2N)2C6H2NH2 (C.A. 34, 37002) heated 15 min. on a steam bath and the cooled mixture poured into 100 ml. ice H2O, stirred 30 min. and filtered, the product washed to neutrality with H2O, and crystallized (120 ml. alc.) gave 9 g. 2,4,5-Me(O2N)2C6H2NHAc (VI), m. 179-80°. VI (8.5 g.) in 95 ml. AcOH and 49 ml. Ac2O treated with 5.2 g. anhydrous KOAc and 0.65 g. P2O5 and the mixture stirred 32 min. with dropwise addition of 3.5 g. NOCl in 16 g. Ac2O, the mixture poured onto 500 g. cracked ice and kept 20 min., the product filtered off and washed well with H2O and finally with petr. ether, the nitroso derivative (8.65 g., m. 170-2°) warmed 12 hrs. at 35° in 425 ml. dry thiophene-free C6H6 and refluxed 24 hrs., the cooled mixture filtered from 5.1 g. VI and the filtrate evaporated in vacuo, the tarry residue extracted 5 times with 100 ml. petr. ether, and the extract evaporated gave 750 mg. 2,1,4,5-MePh(O2N)2C6H2 (VII), m. 118-20° (alc.). VII (3.35 g.) in 50 ml. dioxane hydrogenated 5 hrs. at 20°/1 atmospheric with 1.68 g. 10% Pd-C and the filtered solution treated with 5 ml. 20% HCl in dioxane, filtered, and the product washed with Et2O gave 3.1 g. I.2HCl, m. 240-50° (H2O). I.2HCl (135 mg.) and 105 mg. (PhCO)2 refluxed 4 hrs. in 10 ml. 95% alc. and the cooled solution filtered, the product washed with H2O, and crystallized (alc.) gave 125 mg. 7-methyl-2,3,6-triphenylquinoxaline, m. 145-6°. The low yield led to other unsuccessful attempts to prepare I such as the attempt from the biphenyl derivative, 2,5-Ph(O2N)C6H3Me (VIII). VIII (21.3 g.) in 200 ml. 1:1 alc.-dioxane containing 0.2 ml. 30% NaOH hydrogenated at 20°/25 atmospheric with 20 g. Raney Ni and the filtered solution evaporated in vacuo, the residue diluted with H2O and extracted with EtOAc, the dried (Na2SO4) extract evaporated in vacuo, and the oily product distilled yielded 15 g. 2,5-Ph-(H2N)C6H3Me (IX), b. 133-5°. IX (35.7 g.) acetylated with 100 ml. Ac2O in 20 ml. C5H5N and the mixture kept overnight at room temperature, the solution poured into 400 g. ice and 30 ml.

concentrated HCl, filtered and the residue crystallized (dilute alc.), the product (32 g., m. 125-7°) nitrated at -5° with concentrated HNO3-H2SO4, and the inseparable mixture hydrogenated at 20°/50 atmospheric gave a methyltriaminobiphenyl monoacetate, C15H17N3O, m. 205-6°, saponified to a triamine, unreactive with (PhCO)2 and therefore lacking vicinal NH2 groups. Various other unsuccessful procedures are outlined including transformations of 5-methyl-6-bromobenzimidazole (X), prepared from 4,5,1,2-MeBr(H2N)2C6H2 (XI). XI (5 g., prepared according to Landquist, C.A. 48, 11427b) refluxed 1 hr. in 15 ml. 98% HCO2H and the cooled mixture taken up in 100 ml. H2O, adjusted to pH 8 with 10% NaOH and filtered, the residue washed to neutrality with distilled H2O, and the dried product crystallized (C6H6) yielded 3.95 g. X, m. 196-8°. The synthesis of II by substitution of 2 vicinal NH2 groups for 2 vicinal CO2H groups was studied by model expts. based on phthalic acid. NN-Phthalimidoanthranilic acid (21 g.) in 100 ml. C6H6 refluxed 2 hrs. with 25 g. PCl5 and the mixture cooled (ice-NaCl bath) gave 17.3 g. N,N-phthalimidoanthranilic acid chloride (XII), m. 152-3°. NaN3 (6 g.) in 40 ml. H2O stirred with addition of 17 g. XII and the mixture stirred 1 hr. at room temperature, kept overnight, and filtered gave 17 g. azide, m. 104-5°. The azide (10 g.) refluxed 3 hrs. with 4 g. PhCH2OH in 50 ml. C6H6 and the cooled mixture filtered gave 9 g. of the corresponding benzylcarbamate (XIII), m. 175-6°. XIII (1 g.) dissolved in 10 ml. hot N NaOH and the cooled solution acidified with 10% HCl gave 0.20 g. authentic benzimidazolone (XIV), m. 307-8° (cf. Darapsky and Gaudian, C.A. 31,3979). XIII (2.5 g.) in 100 ml. MeOH and 1 ml. AcOH hydrogenated 3 hrs. at 20°/25 atmospheric with 2 g. Pd-C and the filtered solution neutralized with NaOH, evaporated in vacuo, and the residue crystallized gave XIV, converted by POCl3 in HCl to 2-chlorobenzimidazole and hydrogenated to give the known benzamidazole. The synthesis of V was accordingly undertaken by this procedure. The known 4,5-diphenylphthalic acid (15 g. prepared according to Huggill and Parkinson, Brit. 683,770, C.A. 48, 2776g) and 24 g. PCl5 refluxed 20 hrs. at 150° (H2O-free atmospheric) and the POCl3 evaporated 150°/760 mm. and at 150°/15 mm., the cooled mixture extracted at 50° with petr. ether, and the extract evapd, gave 9 g. 4,5-diphenylphthalic acid chloride (XV), m. 104-5° (petr. ether), similarly obtained from the anhydride prepared by the action of SOCl2. XV (12.3 g.) in 190 ml. Me2CO stirred at 0° with 8.1 g. NaN3 in 45 ml. H2O, the mixture kept 10 min. at 0° and filtered, the residue washed with 50 ml. H2O, and dried at room temperature in vacuo gave 10.5 g. 4,5-diphenyl-1-isocyanatobenzoic acid azide (XVI), m. 117° (decomposition). XVI (9.5 g.) refluxed 4 hrs. in 150 ml. absolute alc. with violent evolution of N, the clear yellow solution cooled to -20° and filtered, the residue washed with 200 ml. 99% alc., and dried at 50° gave 6.8 g. 4,5,1,2-Ph2C6H2(NHCO2Et)2 (XVII), m. 187-9deg;, unchanged on boiling in concentrated HCl or 20% H2SO4. XVII (0.5 g.) refluxed 3 hrs. in 20 ml. 15% KOH and filtered hot gave 370 mg. residue, crystallized (MeOH) to give IV, m. 289-90°, insol. in HCl or dilute or concentrated aqueous NaOH even on heating, contrary to XIV. IV (3.5 g.) heated 3 hrs. at 170° in a sealed Carius tube with 40 ml. POCl3 and 5 drops of concentrated HCl and the cooled mixture treated with ice and made alkaline with 15% NH4OH, filtered, and the dried residue (4 g., m. 190-200°) crystallized (150 ml. MeOH) gave 2.95 g. impure 2-chloro-5,6-diphenylbenzimidazole (XVIII), m. 248-50° (decomposition). XVIII (2.1 g.) in 300 ml. alc. hydrogenated 1 hr. at 20°/1 atmospheric with 1.5 g. Pd-C and the filtered solution evaporated in vacuo, the HCl salt (1.7 g.) treated with 30 ml. hot N NaOH and filtered, the residue washed 3 times with 10 ml. H2O, and dried at 50° gave 0.8 g. V, m. 266-7° (C6H6).

IT **90303-35-8**, Benzoyl chloride, o-phthalimido-
(preparation of)

RN 90303-35-8 CAPLUS
CN Benzoyl chloride, 2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)- (9CI) (CA INDEX NAME)



L12 ANSWER 153 OF 161 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1957:98927 CAPLUS
DOCUMENT NUMBER: 51:98927
ORIGINAL REFERENCE NO.: 51:17819f-i,17820a
TITLE: N-Aryltetrachlorophthalimides and their ability to form molecular complexes
AUTHOR(S): Jacquignon, Pierre; Buu-Hoi, Ng. Ph.
CORPORATE SOURCE: Univ. Paris
SOURCE: Bulletin de la Societe Chimique de France (1957) 935-7
CODEN: BSCFAS; ISSN: 0037-8968
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
GI For diagram(s), see printed CA Issue.
AB cf. C.A. 51, 11016d. Similarly to tetrachlorophthalic anhydride (I), the imide (II) and the N-Ar compds. form complexes (III) with electron donors, but the III are less stable and of lighter color than those of I. III were precipitated from equimolar amts. of II and the following compds. after solution in the min. amount of boiling HOAc and recrystg. from HOAc: pyrene (III, decompose 230°), N-butylcarbazole, N-benzylcarbazole, 3-methyl-2-(p-xenyl)indole. III were yellow needles with indefinite m.ps. IV and II gave a red III, m. 226-7°. N-Phenyltetrachlorophthalimide, m. 275°, gave a III, m. 221°, with 2'isopropyl-1,2,5,6-dibenzocarbazole (VI) and an unstable III with V, which also yielded a III, m. 196°, with I. N-(3,4-Dimethylphenyltetrachlorophthalimide (12 g.), m. 251°, prepared from 5 g. 1,3,4-xylidine and 13 g. I in 100 cc. glacial HOAc (heated) 15 min. and cooled, gave an orange III with V, and a III, m. 161-75°, with IV. I yielded N-aryltetrachlorophthalimides with the following amines (m.p. given): 1,2,3-xylidine, 249°; 1,2,4- and 1,2,5-xylidine, 234° and 265°; o- and p-anisidine, 256° and 265°, o- and p-phenetidine, 216° and 224°; pseudocumidine, 234°; m-ClC6H4NH2, 267°; m- and p-bromoaniline, 272° and 335°; 3,4-ClBrC6H3NH2, 306°; 5,2-Cl(MeO)C6H3NH2, 270°; p-FC6H4NH2, 271° (III with IV, m. 216-30°, and with V, orange); o-CF3C6H4NH2, 243-4°; α-naphthylamine, 239° (III with V, orange); p-aminoacetanilide, 347-8°; p,p'-diaminodiphenylmethane, 367°; 2,4-diaminotoluene, 327°.
IT **340-66-9**, Phthalimide, 3,4,5,6-tetrachloro-N-(α,α,α-trifluoro-o-tolyl)-
(preparation of)
RN 340-66-9 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 4,5,6,7-tetrachloro-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L12 ANSWER 154 OF 161 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1939:36757 CAPLUS
DOCUMENT NUMBER: 33:36757
ORIGINAL REFERENCE NO.: 33:5200h-i
TITLE: Aromatic acid amides
INVENTOR(S): Wolfram, Arthur; Hausdorfer, Emil
PATENT ASSIGNEE(S): I. G. Farbenindustrie AG
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 668743		19381209	DE	

AB Aromatic derivs. of phthalimide (I) are treated with Cl either in a fused state or in a diluent. Thus, fused o-methylphenyl-I is treated with Cl to give o-(trichloromethyl)phenyl-I, m. 153-8°. The preparation of p-(trichloromethyl)phenyl-I, m. 205-10°, 2-(trichloromethyl)-4-chlorophenyl-I, b1 230-34°, 2-(trichloromethyl)-6-chlorophenyl-I, b1 230-5°, 3-chloro-4-(trichloromethyl)phenyl-I, m. 164-6°, 4-(trichloromethyl)-2,5-dichlorophenyl-I, m. 209-11°, 2,6-bis(trichloromethyl)phenyl-I, m. 235-7°, and 2,4-bis(trichloromethyl)phenyl-I, b0.4 254-5°, is also described. The products are used as dye intermediates.

IT **124421-17-6**, Phthalimide, N-[α,α,α,6-tetrachloro-o-tolyl]- **802970-01-0**, Phthalimide, N-(α,α,α,α',α',α'-hexachloro-2,4-xylyl)- **847165-17-7**, Phthalimide, N-[α,α,α,4-tetrachloro-o-tolyl]- **861018-05-5**, Phthalimide, N-(α,α,α,α',α',α'-hexachloro-2,5-xylyl)- **861018-98-6**, Phthalimide, N-(α,α,α-trichloro-o-tolyl)-
(preparation of)

RN 124421-17-6 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-chloro-6-(trichloromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 802970-01-0 CAPLUS

CN Phthalimide, N-(α,α,α,α',α',α'-hexachloro-2,4-xylyl)- (4CI) (CA INDEX NAME)



RN 847165-17-7 CAPLUS
CN Phthalimide, N-[α,α,α,4-tetrachloro-o-tolyl]- (4CI) (CA INDEX NAME)



RN 861018-05-5 CAPLUS
CN Phthalimide, N-(α,α,α,α',α',α'-hexachloro-2,5-xylyl)- (4CI) (CA INDEX NAME)



RN 861018-98-6 CAPLUS
CN Phthalimide, N-(α,α,α-trichloro-o-tolyl)- (4CI) (CA INDEX NAME)



L12 ANSWER 155 OF 161 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1937:46668 CAPLUS
DOCUMENT NUMBER: 31:46668
ORIGINAL REFERENCE NO.: 31:6478h-i,6479a
TITLE: Aromatic acid amides containing the trichloromethyl group
INVENTOR(S): Wolfram, Arthur; Hausdorfer, Emil
PATENT ASSIGNEE(S): General Aniline Works

DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2087715		19370720	US	

GI For diagram(s), see printed CA Issue.

AB By causing Cl to act at temps. of about 120-220° upon compds. of the general formula CO.C6H4.CO.NC6H3(X)CCl3, wherein X means Me, Cl or H, which is present in a liquid form, products (suitable for use as dye intermediates) are obtained such as o-(trichloromethyl)phenylphthalimide, m. 153-8° m-isomer and p-isomer, m. 205-10°, 2-(trichloromethyl)-5-chlorophenylphthalimide, 2-(trichloromethyl)-4-chlorophenylphthalimide, b0.5 230-4°, 2-(trichloromethyl)-6-chlorophenylphthalimide, b1.5 230-5°, 3-chloro-4-(trichloromethyl)phenylphthalimide b1.5 255-8°, 4-(trichloromethyl)-2,5-dichlorophenylphthalimide, b1, 240-5° and m. 209-11°, 2,6-bis(trichloromethyl)phenyl-phthalimide, m. 235-7°, 2,4-isomer, b0.4 254-5° and 2-(trichloromethyl)-3-chlorophenylphthalimide, m. 175-7° (details being given of the production of all these compds.).

IT **124421-17-6**, Phthalimide, N-[α,α,α,6-tetrachloro-o-tolyl]- **714960-24-4**, Phthalimide, N-[α,α,α,5-tetrachloro-o-tolyl]- **714960-77-7**, Phthalimide, N-[α,α,α,3-tetrachloro-o-tolyl]- **802970-01-0**, Phthalimide, N-[α,α,α,α',α',α'-hexachloro-2,4-xylyl]- **847165-17-7**, Phthalimide, N-[α,α,α,4-tetrachloro-o-tolyl]- **861018-05-5**, Phthalimide, N-[α,α,α,α',α',α'-hexachloro-2,5-xylyl]- **861018-98-6**, Phthalimide, N-[α,α,α-trichloro-o-tolyl]-
(preparation of)

RN 124421-17-6 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-chloro-6-(trichloromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 714960-24-4 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[5-chloro-2-(trichloromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 714960-77-7 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[3-chloro-2-(trichloromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 802970-01-0 CAPLUS
CN Phthalimide, N-(α,α,α,α',α',α'-hexachloro-2,4-xylyl)- (4CI) (CA INDEX NAME)



RN 847165-17-7 CAPLUS
CN Phthalimide, N-[α,α,α,4-tetrachloro-o-tolyl]- (4CI) (CA INDEX NAME)



RN 861018-05-5 CAPLUS
CN Phthalimide, N-(α,α,α,α',α',α'-hexachloro-2,5-xylyl)- (4CI) (CA INDEX NAME)



RN 861018-98-6 CAPLUS
CN Phthalimide, N-(α,α,α-trichloro-o-tolyl)- (4CI) (CA INDEX NAME)



L12 ANSWER 156 OF 161 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1937:30730 CAPLUS
DOCUMENT NUMBER: 31:30730
ORIGINAL REFERENCE NO.: 31:4342e-h
TITLE: Aromatic amines containing fluorine
PATENT ASSIGNEE(S): I. G. Farbenindustrie AG
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 459890		19370118	GB	

GI For diagram(s), see printed CA Issue.

AB Amines containing a -CF3 group are prepared by causing HF to react with compds. of the formula O:-C.R'.C(O).N.R.CC3 (R is an aromatic radical and -OC.R'.CO- a radical of an ortho dicarboxylic acid) and eliminating, if desired, the radical of the ortho dicarboxylic acid with known agents. Examples are given of the preparation of o-(trifluoromethyl)- (m. 129-31°), m-(trifluoromethyl)-(m. 148°), 2-(trifluoromethyl)-5-chloro- (m. 197-8°), 2-(trifluoromethyl)-3-chloro-(b1 195-200), 2-(trifluoromethyl)-4-chloro-(b1.3 197-203°, m. 143-5°), 2-(trifluoromethyl)-6-chloro- (b0.2 180-5°) 3-chloro-4-(trifluoromethyl)- (m. 200-2°), 4-(trifluoromethyl)-2,5-dichloro-(m. 182-3°), 2,4-bis(trifluoromethyl)- (b2 185-190°), and 2,6-bis(trifluoromethyl) -phenylphthalimide (b0.2 160-3°), o-(trifluoromethyl)-(b2.5 68-70°), m-(trifluoromethyl)-(b4.5 70-85°), 2-(trifluoromethyl) -5-chloro- (b4 82-4°), 2-(trifluoromethyl) -3-chloro- (b.0.5 55-60°), 2-(trifluoromethyl)-4-chloro- (b3 66-7°), 2-(trifluoromethyl)-6-chloro- (b0.1 39-40°), 3-chloro-4-(trifluoromethyl)- (b10 112-5°), 4-(trifluoromethyl)-2,5-dichloro- (b0.8 95-100°), 2,4-bis(trifluoromethyl)- (b0.4 50°) and 2,6-bis(trifluoromethyl)-aniline (b0.2 37°).

IT **314-11-4**, Phthalimide, N-[α,α,α-trifluoro-o-tolyl]- **340-65-8**, Phthalimide, N-[3-chloro-α,α,α-trifluoro-o-tolyl]- **361-17-1**,

Phthalimide, N-[6-chloro-α,α,α-trifluoro-o-tolyl]- **436-20-4**, Phthalimide, N-[4-chloro-α,α,α-trifluoro-o-tolyl]- **438-39-1**, Phthalimide, N-[5-chloro-α,α,α-trifluoro-o-tolyl]- **2377-33-5**, Phthalimide, N-(α,α,α,α',α',α'-hexafluoro-2,6-xylyl)- **2377-34-6**, Phthalimide, N-(α,α,α,α',α',α'-hexafluoro-2,4-xylyl)-
(preparation of)

RN 314-11-4 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 340-65-8 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[3-chloro-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 361-17-1 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-chloro-6-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 436-20-4 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[4-chloro-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 438-39-1 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[5-chloro-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 2377-33-5 CAPLUS
CN Phthalimide, N-(α,α,α,α',α',α'-hexafluoro-2,6-xylyl)- (8CI) (CA INDEX NAME)



RN 2377-34-6 CAPLUS
CN Phthalimide, N-(α,α,α,α',α',α'-hexafluoro-2,4-xylyl)- (8CI) (CA INDEX NAME)



L12 ANSWER 157 OF 161 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1937:30762 CAPLUS
DOCUMENT NUMBER: 31:30762
ORIGINAL REFERENCE NO.: 31:4346i,4347a,4348a
TITLE: N-(Trichloromethylphenyl)phthalimides
PATENT ASSIGNEE(S): I. G. Farbenindustrie AG
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 459881		19370118	GB	

AB Amides containing a trichloromethyl group are prepared by treating with Cl the corresponding Me compds. at a high temperature The Me compds. are used either in the fused state or in solution with exposure to light. Examples are given of the preparation of o-(trichloromethyl)-(m. 153-8°), m-(trichloromethyl)-, 2-(trichloromethyl)-5-chloro-, p-(trichloromethyl)-(b1 238-42°), 2-(trichloromethyl)-4-chloro- (b0.5 230-4°), 2-(trichloromethyl)-6-chloro- (b1.5 230-5°), 3-chloro-4-(trichloromethyl)- (b1.5 255-8°, m. 164-6°), 4-(trichloromethyl)-2,5-dichloro- (b1 240-5°, m. 209-11°), 2,6-bis(trichloromethyl)- (m. 235-7°), 2,4-bis(trichloromethyl)-(b0.4 254-5°) and 2-(trichloromethyl)-3-chlorophenylphthalimide, b1 (215-25°, m. 175-7°).

IT **124421-17-6**, Phthalimide, N-[α,α,α,6-tetrachloro-o-tolyl]- **714960-24-4**, Phthalimide, N-[α,α,α,5-tetrachloro-o-tolyl]- **714960-77-7**, Phthalimide, N-[α,α,α,3-tetrachloro-o-tolyl]- **802970-01-0**, Phthalimide, N-(α,α,α,α',α',α'-hexachloro-2,4-xylyl)- **802971-38-6**, Phthalimide, N-(α,α,α,α',α',α'-hexachloro-2,6-xylyl)- **847165-17-7**, Phthalimide, N-[α,α,α,4-tetrachloro-o-tolyl]- **861018-98-6**, Phthalimide, N-[α,α,α-trichloro-o-tolyl]-
(preparation of)

RN 124421-17-6 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-chloro-6-(trichloromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 714960-24-4 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[5-chloro-2-(trichloromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 714960-77-7 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[3-chloro-2-(trichloromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 802970-01-0 CAPLUS
CN Phthalimide, N-(α,α,α,α',α',α'-hexachloro-2,4-xylyl)- (4CI) (CA INDEX NAME)



RN 802971-38-6 CAPLUS
CN Phthalimide, N-(α,α,α,α',α',α'-hexachloro-2,6-xylyl)- (4CI) (CA INDEX NAME)



RN 847165-17-7 CAPLUS
CN Phthalimide, N-[α,α,α,4-tetrachloro-o-tolyl]- (4CI) (CA INDEX NAME)



RN 861018-98-6 CAPLUS
CN Phthalimide, N-(α,α,α-trichloro-o-tolyl)- (4CI) (CA INDEX NAME)



L12 ANSWER 158 OF 161 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1937:30729 CAPLUS
DOCUMENT NUMBER: 31:30729
ORIGINAL REFERENCE NO.: 31:4342e-h
TITLE: Aromatic amines containing fluorine
PATENT ASSIGNEE(S): I. G. Farbenindustrie AG
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 805704		19361127	FR	

GI For diagram(s), see printed CA Issue.

AB Amines containing a -CF3 group are prepared by causing HF to react with compds. of the formula O:-C.R'.C(O).N.R.CC3 (R is an aromatic radical and -OC.R'.CO- a radical of an ortho dicarboxylic acid) and eliminating, if desired, the radical of the ortho dicarboxylic acid with known agents. Examples are given of the preparation of o-(trifluoromethyl)- (m. 129-31°), m-(trifluoromethyl)-(m. 148°), 2-(trifluoromethyl)-5-chloro- (m. 197-8°), 2-(trifluoromethyl)-3-chloro-(b1 195-200), 2-(trifluoromethyl)-4-chloro-(b1.3 197-203°, m. 143-5°), 2-(trifluoromethyl)-6-chloro- (b0.2 180-5°) 3-chloro-4-(trifluoromethyl)- (m. 200-2°), 4-(trifluoromethyl)-2,5-dichloro- (m. 182-3°), 2,4-bis(trifluoromethyl)- (b2 185-190°), and 2,6-bis(trifluoromethyl) -phenylphthalimide (b0.2 160-3°), o-(trifluoromethyl)-(b2.5 68-70°), m-(trifluoromethyl)-(b4.5 70-85°), 2-(trifluoromethyl) -5-chloro- (b4 82-4°), 2-(trifluoromethyl) -3-chloro- (b.0.5 55-60°), 2-(trifluoromethyl)-4-chloro- (b3 66-7°), 2-(trifluoromethyl)-6-chloro- (b0.1 39-40°), 3-chloro-4-(trifluoromethyl)- (b10 112-5°), 4-(trifluoromethyl)-2,5-dichloro- (b0.8 95-100°), 2,4-bis(trifluoromethyl)- (b0.4 50°) and 2,6-bis(trifluoromethyl)-aniline (b0.2 37°).

IT **314-11-4**, Phthalimide, N-[α,α,α-trifluoro-o-tolyl]- **340-65-8**, Phthalimide, N-[3-chloro-α,α,α-trifluoro-o-tolyl]- **361-17-1**, Phthalimide, N-[6-chloro-α,α,α-trifluoro-o-tolyl]- **436-20-4**, Phthalimide, N-[4-chloro-α,α,α-trifluoro-o-tolyl]- **438-39-1**, Phthalimide, N-[5-chloro-α,α,α-trifluoro-o-tolyl]- **2377-33-5**, Phthalimide, N-(α,α,α,α',α',α'-hexafluoro-2,6-xylyl)- **2377-34-6**, Phthalimide, N-(α,α,α,α',α',α'-hexafluoro-2,4-xylyl)-
(preparation of)

RN 314-11-4 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 340-65-8 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[3-chloro-2-(trifluoromethyl)phenyl]- (9CI)

(CA INDEX NAME)



RN 361-17-1 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-chloro-6-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



RN 436-20-4 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[4-chloro-2-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



RN 438-39-1 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[5-chloro-2-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



RN 2377-33-5 CAPLUS
CN Phthalimide, N-(α,α,α,α',α',α'-
hexafluoro-2,6-xylyl)- (8CI) (CA INDEX NAME)



RN 2377-34-6 CAPLUS
CN Phthalimide, N-(α,α,α,α',α',α'-hexafluoro-2,4-xylyl)- (8CI) (CA INDEX NAME)



L12 ANSWER 159 OF 161 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1937:30761 CAPLUS
DOCUMENT NUMBER: 31:30761
ORIGINAL REFERENCE NO.: 31:4346i,4347a,4348a
TITLE: N-(Trichloromethylphenyl)phthalimides
PATENT ASSIGNEE(S): I. G. Farbenindustrie AG
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 805492		19361120	FR	

AB Amides containing a trichloromethyl group are prepared by treating with Cl the corresponding Me compds. at a high temperature The Me compds. are used either in the fused state or in solution with exposure to light. Examples are given of the preparation of o-(trichloromethyl)-(m. 153-8°), m-(trichloromethyl)-, 2-(trichloromethyl)-5-chloro-, p-(trichloromethyl)-(b1 238-42°), 2-(trichloromethyl)-4-chloro- (b0.5 230-4°), 2-(trichloromethyl)-6-chloro- (b1.5 230-5°), 3-chloro-4-(trichloromethyl)- (b1.5 255-8°, m. 164-6°), 4-(trichloromethyl)-2,5-dichloro- (b1 240-5°, m. 209-11°), 2,6-bis(trichloromethyl)- (m. 235-7°), 2,4-bis(trichloromethyl)-(b0.4 254-5°) and 2-(trichloromethyl)-3-chlorophenylphthalimide, b1 (215-25°, m. 175-7°).

IT **124421-17-6**, Phthalimide, N-[α,α,α,6-tetrachloro-o-tolyl]- **714960-24-4**, Phthalimide, N-[α,α,α,5-tetrachloro-o-tolyl]- **714960-77-7**, Phthalimide, N-[α,α,α,3-tetrachloro-o-tolyl]- **802970-01-0**, Phthalimide, N-(α,α,α,α',α',α'-hexachloro-2,4-xylyl)- **802971-38-6**, Phthalimide, N-(α,α,α,α',α',α'-hexachloro-2,6-xylyl)- **847165-17-7**, Phthalimide, N-[α,α,α,4-tetrachloro-o-tolyl]- **861018-98-6**, Phthalimide, N-[α,α,α-trichloro-o-tolyl]-
(preparation of)

RN 124421-17-6 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-chloro-6-(trichloromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 714960-24-4 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[5-chloro-2-(trichloromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 714960-77-7 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[3-chloro-2-(trichloromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 802970-01-0 CAPLUS
CN Phthalimide, N-(α,α,α,α',α',α'-hexachloro-2,4-xylyl)- (4CI) (CA INDEX NAME)



RN 802971-38-6 CAPLUS
CN Phthalimide, N-(α,α,α,α',α',α'-hexachloro-2,6-xylyl)- (4CI) (CA INDEX NAME)



RN 847165-17-7 CAPLUS
CN Phthalimide, N-[α,α,α,4-tetrachloro-o-tolyl]- (4CI) (CA INDEX NAME)



RN 861018-98-6 CAPLUS
CN Phthalimide, N-(α,α,α-trichloro-o-tolyl)- (4CI) (CA INDEX NAME)



L12 ANSWER 160 OF 161 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1936:61895 CAPLUS
DOCUMENT NUMBER: 30:61895
ORIGINAL REFERENCE NO.: 30:8227f-i,8228a-c
TITLE: Peganine. XII. Peganine derivatives and their picrolonates
AUTHOR(S): Spath, Ernst; Kuffner, Friedrich; Lintner, Josef
SOURCE: Ber. (1936), 69B, 2052-8
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
GI For diagram(s), see printed CA Issue.
AB cf. C. A. 30, 3826.4. Juneja, Narang and Ray (C. A. 29, 7985.9) reported that fusion of o-H2NC6H4CH2NHCOCH2CH2CO2H (I) with anhydrous NaOAc gave a compound (II), m. 192°, different from 9-pegen-1-one (III) and which therefore must have the structure. According to them, electrolytic reduction of III gave a base C11H14N2 identical with that obtained in the same way from peganine, while II yielded a base of the same composition but forming a different dipicrolonate. On repeating this work, Spath and Platzer (C. A. 30, 3826.4) obtained pure III, m. 191°, from I, but as Narang and Ray (C. A. 30, 5227.8) still maintain that the product obtained from I is different from III, S., K. and L. have again gone over the work of S. and P. I, with the same m. p. as that used by the Indian workers, was heated exactly according to their directions with dry NaOAc in dry H for 1 hr. at 140-50°. The product again was III, identified by mixed m. p. with a sample prepared from o-aminobenzylsuccinimide and yielding pegan with Na and AmOH. In order to

obtain a product having the structure assigned by J., N. and R. to their II, S., K. and L. condensed o-H2NC6H4CH2OMe with succinic anhydride to the acid o-MeOCH2C6H4NHCOCH2CH2-CO2H which, on ring closure by distillation in a high vacuum, gave the compound MeOCH2C6H4N.CO.CH2.CH2.CO, b0.02 150-60° (bath temperature), m. 93-5°. The MeO group was readily replaced by Br but the resulting Br derivative, b1 170-80° (bath temperature), m. 132-4°, with liquid NH3 unexpectedly gave III, not II. J., N. and R. identified the base C11H14N2 which they obtained by electrolytic reduction of peganine and III as a dipicrolonate, m. 207-13°, and, according to the later paper of N. and R., assumed it to be pegan. This dipicrolonate, however, cannot be a salt of pegan but is the dipicrolonate of N-(o-aminobenzyl)-pyrrolidine (IV) which Spath and Platzer had obtained by the same reduction, for while IV always gives a dipicrolonate, pegan forms a monopicrolonate, N. and R. also describe an intermediate product in the electrolytic reduction of peganine which they formulate as pegan-3-ol and analyzed as a dipicrolonate, but S., K. and L. find that pegan-3-ol forms a monopicrolonate. In the preparation of the picrolonates, in order to avoid the carrying along of free picrolonic acid 2 mols. of acid to 1 of base were used and the amount of solvent alc. was so chosen as to certainly hold in solution any possible excess (1 mol.) of picrolonic acid. Monopicrolonates: peganine, m. 177-9° (decomposition); pegan-3-ol, m. 128-9°; 9-pegene, m. 236-7° (decomposition); pegan, m. 191-3°. Dipicrolonate of IV, m. 213-15°.

IT **90163-00-1**, Succinimide, N-(α-bromo-o-tolyl)- (preparation of)

RN 90163-00-1 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[2-(bromomethyl)phenyl]- (9CI) (CA INDEX NAME)



L12 ANSWER 161 OF 161 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1919:4450 CAPLUS

DOCUMENT NUMBER: 13:4450

ORIGINAL REFERENCE NO.: 13:836i,837a-h

TITLE: Action of acylamino acid chlorides on sodiomalonic ester. V

AUTHOR(S): Gabriel, S.; Lowenberg, Bruno

CORPORATE SOURCE: Univ. Berlin

SOURCE: Ber. (1918), 51, 1493-500

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

GI For diagram(s), see printed CA Issue.

AB cf. Immendorfer, C. A. 9, 1913. Dimethyl o-phthalimidobenzoylmalonate (a), C6H4(CO)2NC6H4COCH-(CO2Me)2, unlike the esters C6H4(CO)2NCR2COCH(CO2Me)2 studied in the previous papers and from which it differs in structure only in having an o-C6H4 instead of the CR2 grouping, is not rearranged but is decomposed by NaOEt; does not react with Na in the expected way (formation of a 6-ring compound, MeO2CC6H4CON.CO.CH(CO2Me).CO.C6H4); and its Na salt with MeI gives an O- instead of a C-Me derivative o-Phthalimidobenzoyl chloride, from the acid and PCl5 heated until liquefied and freed from POCl3 in vacuo at 100°, columns from C6H6, m. 152-3°; 28.5 g. in 90 cc. of hot C6H6 are added to a solution of 4.6 g. Na powder and 37 cc. CH2(CO2Me)2 in 200 cc. C6H6; after several

hrs. the resulting Na salt is filtered off, dissolved and precipitated with CO2, giving 12 g. (a), and HCl ppts. a further 7 g. of less pure (a); the first crop deposits from 45 cc. Me2CO 7 g. of pure (a), short, flat prisms, m. 159-61°, gives a cherry-red color with alc. FeCl3. Boiled 0.5 hr. with HI, (a) gives MeI, CO2 and o-amino-acetophenone hydriodide, decompose 150°. If 2 g. (a) in 15 cc. MeOH are treated with 3 cc. of 4% NaOMe the resulting yellow solution soon deposits delicate yellowish white needles of the sodium salt, soluble in H2O with neutral reaction, which when allowed to stand under the mother liquors several hrs. or more quickly when warmed form a colorless solution; this when evaporated to dryness on the H2O bath leaves a resinous residue, about 0.5 g. of which remains undissolved when rubbed with 100 cc. H2O and consists of methyl o-phthalimidobenzoate, rhombohedrons from much MeOH, m. 160-2°, insol. in acids and alkalies, also obtained by warming 2 g. C6H4(CO)2NC6H4COCl with 5 cc. MeOH and 4.5 cc. of 4% NaOMe. The H2O-soluble portion of the product seps. from a little MeOH in flat leaves, m. 145-6°, soluble in alkalies, repptd. by acids, gives no red color with FeCl3; it is monomethyl phthaloylanthranilate, HO2CC6H4CONHC6H4CO2Me, also obtained by cautiously fusing C6H4(CO)2O with H2NC6H4CO2Me and crystallizing from MeOH. The Na salt of (a) heated 1 hr. at 100° with MeI in Me2CO gives the compound C6H4(CO)2NC6H4C(OMe):C(CO2Et)2, flat columns and rhombohedrons from MeOH, m. 148-9°, gives no red color with FeCl3; boiled several hrs. with HCl or HBr it gives C6H4(CO3H)2 and H2NC6H4CO2H, whereas when heated with HI with addition of Ph4I from time to time to destroy the brown color of liberated I it finally yields an almost colorless solution which is gently boiled 2 hrs. more; MeI and CO2 are evolved, the HI is distilled off in vacuo and the residue is crystallized from H2O and 50% AcOH; it seps. in flat needles and 6-sided tables (1.2 g.), m. 248° (decomposition), soluble in alkalies, repptd. by acids, titrates as a diabasic acid with litmus, forms a light blue copper salt, C17H11O5NCu; it is probably HO2CC6H4CH.CH(CO2H).CO.C6H4.NH (b), for when heated 3 hrs. with fuming HCl at 180° it gives CO2, PhNH2 and C6H4.CO.O.CHCH2CO2H, m. 151°. Diethyl-o-phthalimidobenzoylmalonate, prisms, sinters 94°, m. 105-7°, gives a cherry-red color with FeCl3, converted by HI into C6H4(CO2H)2 and o-H2NC6H4Ac and by NaOMe into ethyl phthalimidobenzoate, prisms, m. 108-9°. Ethyl phthaloylanthranilate, broad needles, m. 114-6°, soluble in alkalies. Diethyl [o-phthalimidobenzoyl]ethylmalonate, C6H4(CO)2NC6H4C(OEt):C(CO2Et)2, columns, m. 89-90°. Diethyl [o-phthalimidobenzoyl]methylmalonate, short, rhombohedral prisms, m. 104-6°, converted into (b) by Hl.

IT **90303-35-8**, Benzoyl chloride, o-phthalimido- (preparation of)

RN 90303-35-8 CAPLUS

CN Benzoyl chloride, 2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)- (9CI) (CA INDEX NAME)



```
=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                        63.33     414.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                        -8.03     -10.22

FILE 'REGISTRY' ENTERED AT 10:31:10 ON 27 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   26 DEC 2005  HIGHEST RN 870675-00-6
DICTIONARY FILE UPDATES:  26 DEC 2005  HIGHEST RN 870675-00-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10776828\Struc 5.str
```





chain nodes :

12 13 16
ring nodes :
1 2 3 4 5 6 7 8 9 10 11
chain bonds :
1-12 6-7 8-13 12-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 6-7 7-8 7-11 8-9 8-13 9-10 10-11
exact bonds :
1-12 12-16

G1:O,S

G2:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 16:CLASS

L13 STRUCTURE UPLOADED

=> d
L13 HAS NO ANSWERS
L13 STR



G1 O,S
G2 C,N

Structure attributes must be viewed using STN Express query preparation.

=> l13
SAMPLE SEARCH INITIATED 10:31:29 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 90 TO ITERATE

100.0% PROCESSED 90 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1231 TO 2369
PROJECTED ANSWERS: 0 TO 0

```
L14            0 SEA SSS SAM L13

=> l13 full
FULL SEARCH INITIATED 10:31:33 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      1996 TO ITERATE

100.0% PROCESSED     1996 ITERATIONS                                 10 ANSWERS
SEARCH TIME: 00.00.01

L15           10 SEA SSS FUL L13

=> file caplus medline
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   161.33     576.23

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -10.22

FILE 'CAPLUS' ENTERED AT 10:31:38 ON 27 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 10:31:38 ON 27 DEC 2005

=> l15
L16          10 L15

=> dup rem l15
DUPLICATE IS NOT AVAILABLE IN 'REGISTRY'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     1.03     577.26

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -10.22

FILE 'REGISTRY' ENTERED AT 10:31:47 ON 27 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   26 DEC 2005  HIGHEST RN 870675-00-6
DICTIONARY FILE UPDATES:  26 DEC 2005  HIGHEST RN 870675-00-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
```

```
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html
PROCESSING COMPLETED FOR L15
L17          10 DUP REM L15 (0 DUPLICATES REMOVED)

=> file caplus medline
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                   0.43     577.69

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                   0.00     -10.22

FILE 'CAPLUS' ENTERED AT 10:31:53 ON 27 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 10:31:53 ON 27 DEC 2005

=> dup rem l16
PROCESSING COMPLETED FOR L16
L18          10 DUP REM L16 (0 DUPLICATES REMOVED)

=> d l18 ibib hitstr abs 1-10

L18  ANSWER 1 OF 10  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         2004:370902  CAPLUS
DOCUMENT NUMBER:          140:375065
TITLE:                    Preparation of 2-oxo-1-phenylpyrrolidine-3-
                          carboxamides as herbicides.
INVENTOR(S):              Reinhard, Robert; Hamprecht, Gerhard; Puhl, Michael;
                          Seitz, Werner; Parra Rapado, Liliana; Scannell-Lansky,
                          Annegret; Grossmann, Klaus; Schiffer, Helmut;
                          Witschel, Matthias; Zagar, Cyrill; Landes, Andreas;
                          Rack, Michael
PATENT ASSIGNEE(S):       BASF Aktiengesellschaft, Germany
SOURCE:                   PCT Int. Appl., 108 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 German
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2004037787         A1    20040506    WO 2003-EP11557         20031017
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
```

GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2502478	AA	20040506	CA 2003-2502478		20031017
EP 1556346	A1	20050727	EP 2003-758015		20031017
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
PRIORITY APPLN. INFO.:			DE 2002-10248700	A	20021018
			WO 2003-EP11557	W	20031017

OTHER SOURCE(S): MARPAT 140:375065

IT **685531-71-9P**

RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxophenylpyrrolidinecarboxamides as herbicides)

RN 685531-71-9 CAPLUS

CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-2-oxo-1-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



GI



AB Title compds. [I; R1 = H, OH, Cl, Br, alkyl, cycloalkyl, alkenyl, alkynyl, COR4, CO2R4; R2, R3 = H, (substituted) alkyl, cycloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, Ph, heterocyclyl, etc.; R3NAnR2 = atoms to form a (substituted) 3-7 membered heterocyclyl; R20-R24 = H, OH, cyano, NO2, halo, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, alkoxy, haloalkoxy, alkylthio, COR4, alkoxyalkyl, etc.; X, Y = O, S; n = 0, 1; A = O, S, SO, SO2, NR12; R4 = H, alkyl; R12 = H, alkyl, alkenyl, alkynyl], were prepared Thus, 3-trifluoromethylaniline, butyrolactone, and concentrate HCl were refluxed 13 h to give 85% 1-(3-trifluoromethyl)phenyl-2-pyrrolidinone. The latter in THF at

0° was treated with LDA and 45 min. later with di-Me carbonate in THF followed by warming to 20° and stirring for 72 h to give 34% 2-oxo-1-(3-trifluoromethyl)phenyl-3-pyrrolidinecarboxylic acid. This was stirred with carbonyldiimidazole and aqueous MeNH2 in CH2Cl2 to give 32% 1-(3-trifluoromethyl)phenyl-3-(N-methyl)carboxamido-2-pyrrolidinone. I at 3 kg/ha postemergent gave very good herbicidal activity against e.g. velvetleaf.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:267291 CAPLUS
DOCUMENT NUMBER: 140:303518
TITLE: Preparation of N-aminoacyl pyrrolidine-2-carbonitriles and related compounds as inhibitors of dipeptidyl peptidase-IV (DPP-IV) useful against type II diabetes and other disorders
INVENTOR(S): Madar, David; Pei, Zhonghua; Pireh, Daisy; Djuric, Stevan W.; Wiedeman, Paul E.; Yong, Hong; Feenstra, Melissa J.; Kopecka, Hana; Li, Xiaofeng; Longenecker, Kenton; Sham, Hing L.; Stewart, Kent D.; Szczepankiewicz, Bruce G.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026822	A2	20040401	WO 2003-US29018	20030915
WO 2004026822	A3	20040506		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004121964	A1	20040624	US 2003-659860	20030911
CA 2497725	AA	20040401	CA 2003-2497725	20030915
BR 2003014582	A	20050809	BR 2003-14582	20030915
EP 1560811	A2	20050810	EP 2003-774478	20030915
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:	US 2002-246831	A	20020919
	US 2002-412084P	P	20020919
	US 2003-659860	A	20030911
	WO 2003-US29018	W	20030915

OTHER SOURCE(S): MARPAT 140:303518
IT **676560-45-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-aminoacyl pyrrolidine-2-carbonitriles and related compds. as inhibitors of dipeptidyl peptidase-IV useful against type II diabetes and other disorders)
RN 676560-45-5 CAPLUS
CN Carbamic acid, [trans-4-[3-(2-oxo-1-pyrrolidinyl)-4-

(trifluoromethyl)phenoxy]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



GI



I II

AB The present invention relates to N-aminoacyl pyrrolidine-2-carbonitriles and related compds. (shown as I; variables defined below; e.g. II) that inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia,
Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases (no data). Compds. I inhibit DPP-IV induced fluorescence with inhibitory consts. 0.014-7 μM. Although the methods of preparation are not claimed, >100 example prepns. are included. For example, II was prepared in 9 steps starting from Me (S)-(+)-2-pyrrolidone-5-carboxylate and involving intermediates di-Me (2S)-5-oxopyrrolidine-1,2-dicarboxylate, di-Me (2S)-5-methoxypyrrolidine-1,2-dicarboxylate, di-Me (2S)-5-[(trimethylsilyl)ethynyl]pyrrolidine-1,2-dicarboxylate (separated diastereomers), Me (5R)-5-[(trimethylsilyl)ethynyl]-L-prolinate, Me (5R)-1-[N-(tert-butoxycarbonyl)-L-leucyl]-5-[(trimethylsilyl)ethynyl]-L-prolinate, (5R)-1-[N-(tert-butoxycarbonyl)-L-leucyl]-5-ethynyl-L-proline, (5R)-1-[N-(tert-butoxycarbonyl)-L-leucyl]-5-ethynyl-L-prolinamide and (5R)-1-[N-(tert-butoxycarbonyl)-L-leucyl]-5-ethynyl-L-pyrrolidine-2-carbonitrile. For I: X = CH2, CHF and CF2; R = alkylcarbonyl, arylcarbonyl, cyano, heterocyclecarbonyl, R4R5NC(O)-, B(OR6)2, 1,3,2-dioxaborolane and 4,4,5,5-tetramethyl-1,3,2-dioxaborolane; R1 = alkoxyalkyl, alkyl, alkylcarbonyl, alkenyl, alkynyl, allenyl, arylalkyl, cycloalkyl, cycloalkylalkyl, cyano, haloalkyl, haloalkenyl, heterocyclealkyl, and hydroxyalkyl. R2 and R3 = H, alkoxyalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycle, heterocyclealkyl, hydroxyalkyl; or R2 and R3 taken together with the atoms to which they are attached form a mono or bicyclic heterocycle 2-indolinyl, 2-indolyl, 3-isoquinolinyl, 2-piperazinyl, 2-piperidinyl, 2-pyrrolidinyl, 2-pyrrolyl, 2-pyridinyl, 2-quinolinyl, 2-tetrahydroquinolinyl, and 3-tetrahydroisoquinolinyl, wherein said heterocycle may be substituted with 0-3 alkenyl, alkoxy, alkoxyalkyl,

alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylsulfonyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkyl, arylcarbonyl, aryloxy, carboxy, carboxyalkyl, cyano, cyanoalkyl, formyl, halogen, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, Ph, RARBN-, RcRDNC(O)-, and RcRDNS(O)2-. R4, R5 and R6 = H, alkyl, and arylalkyl; RA and RB = alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl; or RA and RB taken together with the N to which they are attached form a ring piperidine, piperazine and morpholine; and RC and RD = H and alkyl.

L18 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:1127082 CAPLUS
DOCUMENT NUMBER: 142:74441
TITLE: Preparation of N-aminoacyl pyrrolidine-2-carbonitriles and related compounds as inhibitors of dipeptidyl peptidase-IV (DPP-IV) useful against type II diabetes and other disorders
INVENTOR(S): Madar, David J.; Djuric, Stevan W.; Michmerhuizen, Melissa J.; Kopecka, Hana A.; Li, Xiaofeng; Longenecker, Kenton L.; Pei, Zhonghua; Pireh, Daisy; Sham, Hing L.; Stewart, Kent D.; Szczepankiewicz, Bruce G.; Wiedeman, Paul E.; Yong, Hong
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 66 pp., Cont.-in-part of U.S. Ser. No. 659,860.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004259843	A1	20041223	US 2004-788993		20040227
US 2004121964	A1	20040624	US 2003-659860		20030911
US 2005215784	A1	20050929	US 2005-36258		20050113
PRIORITY APPLN. INFO.:			US 2002-412084P	P	20020919
			US 2003-659860	A2	20030911
			US 2004-788993	A2	20040227

OTHER SOURCE(S): MARPAT 142:74441
IT **676560-45-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-aminoacyl pyrrolidine-2-carbonitriles and related compds. as inhibitors of dipeptidyl peptidase-IV useful against type II diabetes and other disorders)
RN 676560-45-5 CAPLUS
CN Carbamic acid, [trans-4-[3-(2-oxo-1-pyrrolidinyl)-4-(trifluoromethyl)phenoxy]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



GI



I II

AB The present invention relates to N-aminoacyl pyrrolidine-2-carbonitriles and related compds. (shown as I; variables defined below; e.g. II) that inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases (no data). Compds. I inhibit DPP-IV induced fluorescence with inhibitory consts. 0.014-7 μM. Although the methods of preparation are not claimed, >100 example prepns. are included. E.g., a 9-step synthesis of II, starting from Me (S)-(+)-2-pyrrolidone-5-carboxylate, was given. For I: X = CH2, CHF and CF2; R = alkylcarbonyl, arylcarbonyl, cyano, heterocyclylcarbonyl, R4R5NC(O)-, B(OR6)2, 1,3,2-dioxaborolane and 4,4,5,5-tetramethyl-1,3,2-dioxaborolane; R1 = alkoxyalkyl, alkyl, alkylcarbonyl, alkenyl, alkynyl, allenyl, arylalkyl, cycloalkyl, cycloalkylalkyl, cyano, haloalkyl, haloalkenyl, heterocyclylalkyl, and hydroxyalkyl. R2 and R3 = H, alkoxyalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycle, heterocyclealkyl, hydroxyalkyl; or R2 and R3 taken together with the atoms to which they are attached form a mono or bicyclic heterocycle 2-indolinyl, 2-indolyl, 3-isoquinolinyl, 2-piperazinyl, 2-piperidinyl, 2-pyrrolidinyl, 2-pyrrolyl, 2-pyridinyl, 2-quinolinyl, 2-tetrahydroquinolinyl, and 3-tetrahydroisoquinolinyl, wherein said heterocycle may be substituted with 0-3 alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylsulfonyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkyl, arylcarbonyl, aryloxy, carboxy, carboxyalkyl, cyano, cyanoalkyl, formyl, halogen, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, Ph, RARBN-, RcRDNC(O)-, and RcRDNS(O)2-. R4, R5 and R6 = H, alkyl, and arylalkyl; RA and RB = alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl; or RA and RB taken together with the N to which they are attached form a ring piperidine, piperazine and morpholine; and RC and RD = H and alkyl.

L18 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:5775 CAPLUS

DOCUMENT NUMBER: 138:89797
TITLE: Preparation of substituted oxazolidinones for combinational therapy in the treatment and/or prophylaxis of thromboembolic diseases
INVENTOR(S): Straub, Alexander; Lampe, Thomas; Pernerstorfer, Josef; Perzborn, Elisabeth; Pohlmann, Jens; Roehrig, Susanne; Schlemmer, Karl-Heinz
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 161 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000256	A1	20030103	WO 2002-EP6237	20020607
WO 2003000256	C2	20030206		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10129725	A1	20030102	DE 2001-10129725	20010620
CA 2451258	AA	20030103	CA 2002-2451258	20020607
EE 200400020	A	20040415	EE 2004-20	20020607
EP 1411932	A1	20040428	EP 2002-738154	20020607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002010941	A	20040608	BR 2002-10941	20020607
CN 1523986	A	20040825	CN 2002-812411	20020607
JP 2004534083	T2	20041111	JP 2003-506901	20020607
NZ 530223	A	20050729	NZ 2002-530223	20020607
BG 108443	A	20050331	BG 2003-108443	20031212
ZA 2003009799	A	20041220	ZA 2003-9799	20031218
US 2004242660	A1	20041202	US 2004-481297	20040628
PRIORITY APPLN. INFO.:			DE 2001-10129725 A	20010620
			WO 2002-EP6237 W	20020607

OTHER SOURCE(S): MARPAT 138:89797
IT **482306-47-8P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and pharmacol. activity of; preparation of substituted oxazolidinones for combinational therapy in the treatment and/or prophylaxis of thromboembolic diseases)
RN 482306-47-8 CAPLUS
CN 2-Thiophenecarboxamide, 5-chloro-N-[[2-oxo-3-[4-(2-oxo-1-pyrrolidinyl)-3-(trifluoromethyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



IT **482306-13-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with carbonyldiimdazole; preparation of substituted
oxazolidinones for combinational therapy in the treatment and/or prophylaxis of thromboembolic diseases)
RN 482306-13-8 CAPLUS
CN 2-Thiophenecarboxamide, 5-chloro-N-[2-hydroxy-3-[[4-(2-oxo-1-pyrrolidinyl)-3-(trifluoromethyl)phenyl]amino]propyl]- (9CI) (CA INDEX NAME)



IT **69131-62-0P**, 1-[4-Amino-2-(trifluoromethyl)phenyl]-2-pyrrolidinone
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted oxazolidinones for combinational therapy in the treatment and/or prophylaxis of thromboembolic diseases)
RN 69131-62-0 CAPLUS
CN 2-Pyrrolidinone, 1-[4-amino-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to combinations of (A) oxazolidinones I [R1 = 5-X-2-thienyl (X = Cl, Br, Me, CF3); R2 = DA; A = phenylene; D = 5- or 6-membered heterocyclic ring containing S, N or O; R4 - R8 = H], or their

pharmaceutically acceptable salts, hydrates, prodrugs or their mixts. and (B) other pharmaceutically active ingredients; to a method for producing said combinations; and to the use thereof as medicaments, in particular for the treatment and/or prophylaxis of thrombo-embolic diseases. Thus, the claimed oxazolone II was prepared from epoxide III via epoxide ring opening with aniline derivative IV, cyclization with carbonyldiimidazole, and N-acylation with 5-chlorothiophene-2-sulfonyl chloride. II was tested for antithrombotic activity in the arteriovenous shunt model (Rat) after [ED50 = 3 mg/kg (p.o.); IC50 = 0.7 nM]; II had a synergistic effect when used in combination with clopidogrel.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:462305 CAPLUS
DOCUMENT NUMBER: 125:114610
TITLE: Preparation of pyrazolo[3,4-c]pyridines as inhibitors of phosphodiesterase type IV and production of tumor necrosis factor
INVENTOR(S): Duplantier, Allen J.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9612720	A1	19960502	WO 1995-IB847		19951006
W: AU, CA, CN, CZ, HU, JP, KR, NO, NZ, PL, RU, US					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
CA 2201728	AA	19960502	CA 1995-2201728		19951006
AU 9535317	A1	19960515	AU 1995-35317		19951006
AU 702105	B2	19990211			
EP 787132	A1	19970806	EP 1995-932148		19951006
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
CN 1161040	A	19971001	CN 1995-195743		19951006
CN 1050129	B	20000308			
JP 09511758	T2	19971125	JP 1995-513751		19951006
HU 77517	A2	19980528	HU 1997-2289		19951006
FI 9504991	A	19960421	FI 1995-4991		19951019
ZA 9508839	A	19970421	ZA 1995-8839		19951019
BR 9504491	A	19970520	BR 1995-4491		19951020
NO 9701811	A	19970618	NO 1997-1811		19970418
AU 9892402	A1	19990121	AU 1998-92402		19981113
PRIORITY APPLN. INFO.:			US 1994-326434	A	19941020
			US 1993-88292	A	19930706
			AU 1994-68057	A3	19940616
			AU 1995-35317	A3	19951006
			WO 1995-IB847	W	19951006

OTHER SOURCE(S): CASREACT 125:114610; MARPAT 125:114610
IT **162142-35-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolo[3,4-c]pyridines as inhibitors of phosphodiesterase type IV and production of tumor necrosis factor)
RN 162142-35-0 CAPLUS
CN 2-Pyrrolidinone, 1-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



GI



I



II

AB The title compds. [I; R1 = H, C1-3 alkyl, C2-3 alkenyl, etc.; R2, R3 = H, C1-14 alkyl, C1-14 alkoxy, etc.; X = O, H2], useful in the treatment of asthma, arthritis, bronchitis, psoriasis, allergic rhinitis, dermatitis, AIDS, septic shock, etc., were prepared Thus, cyclization of tetrahydropyridine II with cyclohexylhydrazine.HCl in MeOH afforded I [R1 = Et; R2 = 3-MeC6H4; R3 = cyclohexyl; X = O]. In general, compds. I are effective at 0.3-5 mg/kg body weight per day.

L18 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:480325 CAPLUS
DOCUMENT NUMBER: 122:239696
TITLE: Preparation of tetrahydropyrazolo[3,4-c]pyridines as inhibitors of phosphodiesterase IV or the production of tumor necrosis factor.
INVENTOR(S): Duplantier, Allen Jacob
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9501980	A1	19950119	WO 1994-IB156	19940616
W: AU, BR, CA, CN, CZ, HU, JP, KR, NO, NZ, PL, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9468057	A1	19950206	AU 1994-68057	19940616
AU 695301	B2	19980813		
EP 707585	A1	19960424	EP 1994-916370	19940616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 08507084	T2	19960730	JP 1994-503938	19940616
JP 2944048	B2	19990830		
BR 9406946	A	19960806	BR 1994-6946	19940616
CN 1129940	A	19960828	CN 1994-193233	19940616
CN 1048015	B	20000105		

HU 74170	A2	19961128	HU 1995-3934		19940616
RU 2131876	C1	19990620	RU 1996-103653		19940616
CA 2166721	C	19990727	CA 1994-2166721		19940616
IL 110175	A1	20000131	IL 1994-110175		19940630
FI 9403208	A	19950107	FI 1994-3208		19940705
ZA 9404844	A	19960105	ZA 1994-4844		19940705
NO 9600056	A	19960105	NO 1996-56		19960105
AU 9892402	A1	19990121	AU 1998-92402		19981113
PRIORITY APPLN. INFO.:			US 1993-88292	A	19930706
			AU 1994-68057	A3	19940616
			WO 1994-IB156	W	19940616
			US 1994-326434	A	19941020
			AU 1995-35317	A3	19951006

OTHER SOURCE(S): MARPAT 122:239696

IT **162142-35-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of tetrahydropyrazolo[3,4-c]pyridines as inhibitors of phosphodiesterase IV or the production of tumor necrosis factor)

RN 162142-35-0 CAPLUS

CN 2-Pyrrolidinone, 1-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



GI



AB Title compds. [I; R1 = H, (substituted) alkyl, alkenyl, methylenecycloalkyl; X = O, H2; R2, R3 = H, alkyl, alkoxy, alkenyl, heterocyclyl, Q1, etc.; a = 1-5; b, c = 0, 1; R4 = H, OH, alkyl, alkenyl, alkoxy, cycloalkoxy, halo, CF3, NO2, etc.], were prepared for treatment of asthma, arthritis, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, dermatitis and other inflammatory diseases, AIDS, septic shock and other diseases involving the production of TNF (no data). Thus, 3-hydroxy-2-oxo-1-phenyl-4-propionyl-1,2,5,6-tetrahydropyridine, 4-methoxyphenylhydrazine hydrochloride, and NaOMe were refluxed 12 h in EtOH to give 3-ethyl-1-(4-methoxyphenyl)-6-phenyl-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine.

L18 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1983:575601 CAPLUS

DOCUMENT NUMBER: 99:175601

TITLE: N-Phenyl-substituted N-heterocyclic compounds and

their use in agents for regulating plant growth
INVENTOR(S): Tobler, Hans; Foery, Werner; Schurter, Rolf
PATENT ASSIGNEE(S): Ciba-Geigy Corp. , USA
SOURCE: U.S., 22 pp. Cont.-in-part of U.S. Ser. No. 111,517, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4394156	A	19830719	US 1981-314620	19811026
CH 629076	A	19820415	CH 1977-4702	19770415
CH 632131	A	19820930	CH 1977-13661	19771109
US 4208202	A	19800617	US 1978-896970	19780412
BE 865979	A1	19781016	BE 1978-186784	19780414
ZA 7802158	A	19790328	ZA 1978-2158	19780414
US 4294606	A	19811013	US 1980-111552	19800114

PRIORITY APPLN. INFO.:
CH 1977-4702 A 19770415
CH 1977-13661 A 19771109
US 1978-896970 A3 19780412
US 1980-111517 A2 19800114

OTHER SOURCE(S): CASREACT 99:175601

IT **69131-62-0P 69132-14-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 69131-62-0 CAPLUS
CN 2-Pyrrolidinone, 1-[4-amino-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 69132-14-5 CAPLUS
CN Methanesulfonamide, 1,1,1-trifluoro-N-[4-(2-oxo-1-pyrrolidinyl)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



GI



I



II

AB Phenylpyridones I (R = substituted 2-oxo-1-pyridyl; R1, R2 = H, alkyl, alkoxy, halogen) are claimed. I (R = oxopyrrolidino, oxopiperidino, oxoazetidino, maleimido) were prepared Thus, 4,6,3-Me2(O2N)C6H2NHCO(CH2)4Cl was cyclized, reduced to the amine, and treated with (CF3SO2)2O to give II which was an ineffective herbicide at 0.1 kg/ha preemergence.

L18 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1978:529391 CAPLUS
DOCUMENT NUMBER: 89:129391
TITLE: Herbicidal N-(3-amino-2,4-dinitro-6-trifluoromethylphenyl)pyrrolidones
INVENTOR(S): Schneider, Louis; Graham, David E.
PATENT ASSIGNEE(S): GAF Corp., USA
SOURCE: U.S., 4 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4087270	A	19780502	US 1977-773817	19770303
PRIORITY APPLN. INFO.:			US 1977-773817 A	19770303

IT **67645-69-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and herbicidal activity of)
RN 67645-69-6 CAPLUS
CN 2-Pyrrolidinone, 1-[3-(diethylamino)-2,4-dinitro-6-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



GI



I



II

AB Herbicidal pyrrolidones I (R, R1, R2 = H or C1-C4 alkyl, Z = O or S) were prepared Thus, a mixture the chloride II and Na pyrrolidone in DMF was heated 21.5 h at 112-15° to give 5.0% I (R = H, R1 = R2 = Et, Z = O), which controlled Japanese millet and crabgrass.

L18 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1979:121396 CAPLUS
DOCUMENT NUMBER: 90:121396
TITLE: Plant growth regulating N-phenyl-substituted N-heterocyclic compounds
INVENTOR(S): Tobler, Hans; Foery, Werner; Schurter, Rolf
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: Ger. Offen., 77 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2815820	A1	19781026	DE 1978-2815820	19780412
DE 2815820	C2	19891228		
CH 629076	A	19820415	CH 1977-4702	19770415
CH 632131	A	19820930	CH 1977-13661	19771109
NL 7803885	A	19781017	NL 1978-3885	19780412
FR 2387219	B1	19821119	FR 1978-10761	19780412
FR 2387219	A1	19781110		
DD 137655	C	19790919	DD 1978-204774	19780413
AU 7835084	A1	19791018	AU 1978-35084	19780413
AU 520407	B2	19820128		
CA 1102801	A1	19810609	CA 1978-301079	19780413
IL 54501	A1	19820930	IL 1978-54501	19780413
BE 865979	A1	19781016	BE 1978-186784	19780414
DK 7801646	A	19781016	DK 1978-1646	19780414
SE 7804244	A	19781016	SE 1978-4244	19780414
BR 7802330	A	19790213	BR 1978-2330	19780414
ZA 7802158	A	19790328	ZA 1978-2158	19780414
ES 468807	A1	19791216	ES 1978-468807	19780414
GB 1593809	A	19810722	GB 1978-14762	19780414
AT 7802640	A	19820815	AT 1978-2640	19780414
AT 370280	B	19830310		
HU 185923	B	19850328	HU 1978-CI1825	19780414
CS 274252	B2	19910411	CS 1978-2445	19780414
JP 53130652	A2	19781114	JP 1978-44739	19780415
JP 03021545	B4	19910322		

PRIORITY APPLN. INFO.: CH 1977-4702 A 19770415
CH 1977-13661 A 19771109
OTHER SOURCE(S): CASREACT 90:121396
IT **69131-62-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with trifluoromethanesulfonic anhydride)

RN 69131-62-0 CAPLUS
CN 2-Pyrrolidinone, 1-[4-amino-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT **69132-14-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 69132-14-5 CAPLUS
CN Methanesulfonamide, 1,1,1-trifluoro-N-[4-(2-oxo-1-pyrrolidinyl)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



GI



I



II

AB Trifluoromethanesulfonamides I (NRR1 = optionally substituted N heterocycle; R2-R4 = H, halogen, C1-4 alkyl, haloalkyl, CN, NO2, CSNH2, optionally substituted CH2Ph, alkylthio, alkylsulfinyl, alkylsulfenyl, alkoxy, acyloxy, CO2H, alkoxycarbonyl) were prepared for use as herbicides and plant growth inhibitors (no data). Thus, 3,4,6-O2N(Me2)C6H2NHCOCH2CH2Cl was cyclized and hydrogenated to give II (R5 = H) which was treated with (CF3SO2)2O to give II (R5 = SO2CF3).

L18 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1970:445160 CAPLUS
DOCUMENT NUMBER: 73:45160

TITLE: 3,3-Dichloro-2-oxopolymethylenimines
PATENT ASSIGNEE(S): Sterling Drug Inc.
SOURCE: Brit., 35 pp.
CODEN: BRXXAA
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1192670		19700520	GB	
US 3549654		19700000	US	
US 3647782		19720000	US	
US 3708473		19730000	US	
US 3862172		19750000	US	
PRIORITY APPLN. INFO.:			US	19671009

IT **27474-14-2P 27474-21-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 27474-14-2 CAPLUS
CN 2-Pyrrolidinone, 3,3-dichloro-1-(α,α,α-trifluoro-o-tolyl)- (8CI) (CA INDEX NAME)



RN 27474-21-1 CAPLUS
CN 2-Pyrrolidinone, 3,3-dichloro-1-(4-chloro-α,α,α-trifluoro-o-tolyl)- (8CI) (CA INDEX NAME)



GI For diagram(s), see printed CA Issue.
AB The title compds. (I, II, III) are prepared by cyclization in the presence of an acid acceptor of ClCH2CH2CCl2CONHR or ClCH2(CH2)nCH2CONHR (IV); of [ClCH2CH2CCl2CONH(CmH2m)]2Ar or [ClCH2(CH2)nCH2CONH(CmH2m)]2Ar (V); and of (ClCH2CH2CCl2CONH)2Y or [ClCH2(CH2)nCH2CONH]2Y (VI), and further treating the cyclized compds. from IV, V and VI with a chlorinating agent, and, if desired, hydrolyzing a compound wherein R is a radical substituted by

lower-alkanoylamino or lower-alkanoyloxy to obtain the compound wherein R is a radical substituted by amino or hydroxy groups, resp. (ClCH2CH2CCl2CONH)2Ar where Ar is biphenylene or substituted biphenylene, are useful intermediates in the preparation of II. In all, 50 examples were given, with phys. consts. for most of the products. Many other compds. were cited. I, II, and III have anti-inflammatory properties on administration of multiple doses orally to fasting male albino rats, in doses ranging from 25-400 mg/kg.

```
=> file caplus medline scisearch
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      51.13     628.82

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -7.30     -17.52

FILE 'CAPLUS' ENTERED AT 10:33:25 ON 27 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 10:33:25 ON 27 DEC 2005

FILE 'SCISEARCH' ENTERED AT 10:33:25 ON 27 DEC 2005
Copyright (c) 2005 The Thomson Corporation

=> cherney
L19         42 CHERNEY

=> carter
L20       2836 CARTER

=> duncia
L21          2 DUNCIA

=> gardner
L22       7410 GARDNER

=> santella
L23         22 SANTELLA

=> l19-l23
L24      10311 (L19 OR L20 OR L21 OR L22 OR L23)

=> l19 and l20 and l21 and l22 and l23
L25          0 L19 AND L20 AND L21 AND L22 AND L23

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      12.50     641.32

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00     -17.52

STN INTERNATIONAL LOGOFF AT 10:34:04 ON 27 DEC 2005
```